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ABSTRACT 
 
Quetiapine, an atypical antipsychotic drug, is effective in treating the behavioural and the 
psychological symptoms of dementia (BPSD). The objective of this study was to examine the 
effects of quetiapine on anxiety-like behaviour in the amyloid precursor protein (APP)/ 
presenilin 1 (PS1) double transgenic mouse model of Alzheimer’s disease (AD). The mice were 
treated with quetiapine (0, 2.5, or 5 mg/kg/day) orally in drinking water for 7 or 10 months 
starting from 2 months of age. Conditioned anxiety was measured using the elevated T-maze 
(ETM). To measure memory, the Y-maze and the Morris Water maze were employed. After 
behavioural testing, β-amyloid (Aβ) plaques in the hippocampus and cortex of transgenic mice 
were stained using Congo Red. Brain-derived neurotrophic factor (BDNF) in the basolateral 
amygdala (BLA) and the hippocampus of mice was examined using immunohistochemical 
methods. The statistics revealed an interaction between quetiapine and APP/PS1 double 
transgenic mice in the avoidance phase of the ETM. Quetiapine modulates anxiety-like 
behaviours in the ETM. The anxiety-like behaviours were associated with reductions in BDNF 
levels in the BLA and hippocampus of the transgenic mice. This was reversed by treatment with 
quetiapine. Furthermore, chronic administration of quetiapine attenuated the memory impairment 
and decreased the Aβ plaque load in the brain. This study demonstrates that quetiapine 
normalizes anxiety-like behaviour and up-regulates cerebral BDNF levels in the APP/PS1 mice, 
suggesting that quetiapine may function as a neuroprotectant as well as an antipsychotic in 
treating the BPSD associated with AD.  
 
 
 
 
 
 
 
 
 
 
 iii 
 
DEDICATION 
 
This thesis is dedicated to my dear grandparents, Rene and John. Grandma, you are the reason 
that I take this project personal. Grandpa, with your constant rising to battle with grandma every 
day, I learned to perceive alzheimer’s from a different angle then a purely memory based 
condition. Realizing that along with the deep love you share with grandma, managing her anxiety 
and behaviour changes truly can help improve one’s quality of life. This dedication represents 
the undercurrent that propelled this thesis along.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
ACKNOWLEDGEMENTS 
 
I extend my gratitude to Dr. Xin-Min Li and Dr. J. Steven Richardson. Their supervision, 
ongoing encouragement and unwavering support—personal and professional—throughout the 
evolution of this process have strengthened my passion and commitment in research. Dr. Li’s 
high standard for excellence has also challenged my research potential as a Master’s student in 
the Neuropsychiatric Research Unit. He created an experience that not only improved my 
knowledge of neuroscience and the techniques associated with its study but also expressed his 
belief in me by offering me the opportunity to independently develop my ideas on this thesis 
project and by enabling me to participate in International and Local conferences. Dr. 
Richardson’s open-door policy, patience, expertise in pharmacology and certainly his keen ear to 
my ideas in drug treatment were inspiring. For this, I am most grateful. Thank you. I thank Dr. 
Darrell D. Mousseau for his guidance and belief in my study. I am also thankful to my external 
examiner, Dr. Phyllis G. Paterson, for her guidance and particulary for her perceptive feedback 
on many aspects of this thesis. 
Throughout my training as a Master’s student, I have been most fortunate to work with 
colleagues who not only embraced my ideas and helped with my advancement in neurobiological 
research in psychiatry in countless ways but also shared a memorable friendship with me. 
Therefore, I express special thanks to Dr. Jue He, for his exceptional mentorship. Dr. He’s 
humble demeanour and expertise motivated me to excel at experimental techniques for cognitive 
and behaviour testing as well as protein analysis—all essential areas for the success of this thesis. 
He was always patient with my independent developments of this thesis project, yet offered me 
critical feedback when necessary. Without his expertise this project would not have become an 
epic undertaking.  
I also thank my colleagues and friends in the lab, namely Dr. Yanbo Zhang for his 
thought-provoking discussions and invaluable input into the development of my thesis. I thank 
Dr. Bin Yan for supporting my endeavours and for her wonderful friendship, and I thank my 
fellow graduate students, Yanlin Wang and Shenghua Zhu, whose unconditional support and 
challenging conversations have also strengthened my convictions in neuropsychiatric research. 
Thank you. The other students and post-doctoral fellows at the NRU, I also thank. They all 
contributed to making the NRU a stimulating and a pleasant place to work. 
 v 
 
I would like to offer a special thank-you to Mrs. Gabriel Stegeman for her wonderful 
technical assistance. She taught me a long list of procedures; To Mr. Rene Mag-atas for his 
knowledge and wisemanship; To Dr. Jennifer Chlan-Fourney for her assistance with the 
microscope; To Monica Novotny for her assistance with the statistical analysis and interpretation 
of the results. 
I would also like to thank the mice in this study, as well as all research animals in general 
for their contribution. Without their valuable existence our advancement in knowledge of and 
treatment in the medical sciences would not be this far. 
I would lastly like to thank my fiancée for her unending love and support as well as edits. 
My parents, brother and sister, grandparents, rest of family and friends: they never questioned 
my ambitions-just always expressed their love and support. Their unconditional support was 
critical to my success.  
These experiences have allowed me to improve as a person and have created new 
prospects for my future. For all of this, I am most grateful.  
Part of this thesis was supported by an Alfred E. Molstad Trust graduate award from the 
Department of Psychiatry, University of Saskatchewan.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
TABLE OF CONTENTS 
 
PERMISSION TO USE   ............................................................................................................................ i
ABSTRACT   ............................................................................................................................................ ii
DEDICATION   ....................................................................................................................................... iii
ACKNOWLEDGEMENTS   .................................................................................................................... iv
TABLE OF CONTENTS  ........................................................................................................................ vi
LIST OF TABLES   ................................................................................................................................viii
LIST OF FIGURES   ................................................................................................................................ ix
LIST OF ABBREVIATIONS   ................................................................................................................. xi
CHAPTER 1: INTRODUCTION   ............................................................................................................ 1
1.1 Neurobiological/Neuropsychological Basis of Alzheimer’s Disease: Amyloid Cascade Hypothesis   4
1.2 Potential Factors Involved in Anxiety and Alzheimer’s Disease   ..................................................... 5
1.2.1 Anxiety   .................................................................................................................................... 6
1.2.2 Clinical Anxiety in Alzheimer’s Disease   .................................................................................. 7
1.2.3 Cognition and Anxiety   ............................................................................................................. 8
1.3 The Neurobiological/Neuropsychological Basis of Anxiety   ............................................................ 9
1.3.1 Anxiety Circuit   ........................................................................................................................ 9
1.3.2 Amygdala   ................................................................................................................................ 9
1.3.3 Hippocampus   ........................................................................................................................ 12
1.3.4 Serotonin   .............................................................................................................................. 15
1.3.5 Avoidance and Escape  ........................................................................................................... 17
1.4 APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease   ......................................................... 18
1.4.1 Relevance of Transgenic Mouse Studies to Clinical Trials   ..................................................... 18
1.4.2 Anxiety-Like Behaviour in APP/PS1   ...................................................................................... 20
1.5 Behavioural Testing: The Elevated T Maze   .................................................................................. 21
1.5.1 Overview of the Elevated T-Maze (ETM)   ............................................................................... 21
1.5.2 Pharmacological Studies Using the ETM   .............................................................................. 23
1.5.3 Neuronal Connectivity and Anxiety  ........................................................................................ 25
1.6 Quetiapine’s Effect in Alzheimer’s Disease   .................................................................................. 26
1.6.1 Atypical Antipsychotics   ......................................................................................................... 26
1.6.2 Neuroprotective Properties of Quetiapine and Other Atypical Antipsychotics   ........................ 28
1.6.3 Neurogenesis, Atypical Antipsychotics and Alzheimer’s disease  ............................................. 30
 vii 
 
1.6.4 Atypical Antipsychotics Including Quetiapine: Effects in Alzheimer’s Disease and the APP/PS1 
Transgenic Mouse Model   ............................................................................................................... 31
CHAPTER 2: METHODOLOGY  .......................................................................................................... 34
2.1. Experimental Design   ................................................................................................................... 34
2.1.1 General Hypothesis   ............................................................................................................... 34
2.1.2 Study Design Analysis   ........................................................................................................... 34
2.1.4 Animals   ................................................................................................................................. 35
2.1.3 Drug Treatment  ..................................................................................................................... 38
2.2. Behavioural Testing   .................................................................................................................... 38
2.2.1 Anxiety: Elevated T-Maze   ...................................................................................................... 38
2.2.2 Y-Maze Test   .......................................................................................................................... 42
2.2.3 Water Maze Test   ................................................................................................................... 42
2.3 Tissue Processing and Histology   .................................................................................................. 43
2.3.1 BDNF Level Measurements   ................................................................................................... 43
2.3.2 Staining and Quantification of Amyloid Deposits   ................................................................... 44
2.4 Statistical Analysis   ....................................................................................................................... 45
CHAPTER 3: RESULTS   ....................................................................................................................... 46
3.1. Conditioned Anxiety and Unconditioned Anxiety in the ETM   ..................................................... 46
3.1.1. Avoidance   ............................................................................................................................ 46
3.1.2. Escape   ................................................................................................................................. 46
3.2. BDNF Levels in the Basolateral Amgydala and the Hippocampus   ............................................... 47
3.2.1. Basolateral Amygdala   .......................................................................................................... 47
3.2.2. Hippocampus   ....................................................................................................................... 47
3.3. β-Amyloid Plaque Formation in APP/PS1 Mice Treated With Quetiapine   ................................... 56
3.4. Y-Maze Spatial Working Memory in APP/PS1 Mice Compared With Control   ............................ 56
CHAPTER 4: DISCUSSION   ................................................................................................................. 64
4.1 Report of Aβ plaque load and memory impairment   ...................................................................... 65
4.2. Phenotype of Conditioned Anxiety and Unconditioned Anxiety in the ETM   ................................ 66
4.3. Chronic Administration of Quetiapine: Effect on Conditioned Anxiety   ........................................ 67
4.4. Role of BDNF in BLA and Hippocampus   ................................................................................... 67
4. 5. General Discussion and Implications of Future Research   ............................................................ 69
 
 viii 
 
LIST OF TABLES 
 
Table 1. Number of Mice in Each Group......................................................................................37 
 ix 
 
LIST OF FIGURES 
 
Figure 1. Diagram of the signal cascades linking the initial physiological events by which fear 
conditioning modulates the expression of BDNF in the lateral amygdala (LA).   ................. 14
 
Figure 1. PCR photographic representation of complementary DNA obtained from double 
transgenic APP/PS1 mouse carrier and single transgenic PS1 or APP mice carriers..........36 
 
Figure 3. Schematic representation of the elevated T-maze (ETM).   ........................................... 40
 
Figure 4. Model of the elevated T-maze (ETM) behavioural procedure.   .................................... 41
 
Figure 5. Avoidance in the elevated T-maze in female mice.   ..................................................... 48
 
Figure 6. Escape in the elevated T-maze in female mice.   ........................................................... 49
 
Figure 7. Representative photomicrograph of BDNF immunostaining in the amygdala of a 12 
month old female mice treated with quetiapine for 10 months.  ........................................... 50
 
Figure 8. Quantitative analysis of BDNF-positive cells in the BLA (Basolateral Amygdala) of 
12-month old female mice.   ................................................................................................ 51
 
Figure 9. Representative photomicrographs of BDNF immunostaining in the BLA (Basolateral 
amygdala) in 12-month old female mice.   ........................................................................... 52
 
Figure 10. Representative photomicrograph of BDNF immunostaining in the hippocampus of a 
12-month old female mice treated with quetiapine for 10 months.   ..................................... 53
 
Figure 11. Quantitative analysis of BDNF-positive cells in the Hippocampus (CA1, CA2, CA3, 
DG) of 12-month old female mice.   .................................................................................... 54
 
Figure 12. Representative photomicrographs of BDNF immunostaining in CA1 pyramidal cell 
layers of the hippocampus in 12-month old female mice.   ................................................... 55
 
Figure 13. Representative photomicrographs of Congo Red staining showing Aβ plaques in the 
cortex and hippocampus of 9-month of age APP/PS1 mice.   ............................................... 58
 
Figure 14. Quantitative analysis of plaques by Congo Red staining in the cortex and 
hippocampus.   .................................................................................................................... 59
 
Figure 15. Representative photomicrographs of Congo Red staining showing Aβ plaques in the 
hippocampus and BLA of 12-month of age APP/PS1 mice.   ............................................... 60
 
Figure 16. Y-maze test in 9-month old mice.   ............................................................................. 61
 
 x 
 
Figure 17. Escape latency of the hidden-platform test and percentage of time in the probe test.   . 63
 
Figure 18. Conceptual model of Alzheimer’s disease and quetiapine’s therapeutic effects through 
BDNF.  ............................................................................................................................... 71
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
 
LIST OF ABBREVIATIONS 
 
5-HT  Serotonin 
5-HT1AR Serotonin1A Receptors 
Aβ   Beta Amyloid 
AD   Alzheimer’s Disease 
ANOVA Analysis of Variance 
APP   Amyloid Precursor Protein  
BDNF  Brain-Derived Neurotrophic Factor 
BLA  Basolateral Amygdala 
BNST  Bed Nucleus of the Stria Terminalis 
BPSD   Behavioural and Psychological Symptoms of Dementia  
CA1   Cornu Ammonis 1  
CA2   Cornu Ammonis 2 
CA3   Cornu Ammonis 3 
CAA  Cerebral Amyloid Angiopathy 
CaMKIV  Calcium/Calmodulin-dependent Kinase IV 
cAMP  Cyclic Adenosine Monophosphate 
CREB  cAMP Response Element Binding 
DA  Dopamine  
DG  Dentate Gyrus. 
DZP  Diazepam 
EO  Early-Onset 
EPM  Elevated Plus Maze 
ETM   Elevated T-Maze 
FAD   Familial Alzheimer’s Disease 
GAD   Generalized Anxiety Disorder 
LA  Lateral Amygdala 
L-VDCCs L-type Voltage-dependent Calcium Channel 
NA  Noradrenaline 
NMDA N-methyl-D-aspartate  
PBS  Phosphate-buffered Saline 
PCR  Polymerase chain reaction 
PD  Panic Disorder 
PKA  Protein Kinase A 
PS1   Presenilin 1 
Q5   Quetiapine 5 mg/kg/day 
SPECT Single Positron Emission Computed Tomography 
SSRI  Serotonin Selective Reuptake Inhibitors 
SP  Substance P 
TCA  Tricyclic Antidepressants 
Tg   Transgenic 
 1 
 
CHAPTER 1: INTRODUCTION 
 
Alzheimer’s disease (AD), the most common form of dementia, accounts for roughly half 
of all patients with dementia. AD is a neurodegenerative condition that is distinguished by 
extracellular senile plaques and intracellular neurofibrilliary tangles. Theoretically, these 
pathological changes eventually lead to brain atrophy, as well as synaptic loss and cell death 
(Selkoe & Podlisny, 2002; Storey & Cappai, 1999; Suh & Checler, 2002; Van Gassen & 
Annaert, 2003). Epidemiological investigations of AD found prevalence rates of 5% in 
Canadians over age 65 (Canadian Study of Health and Aging Work Group, [CSHA], 1994), and 
placed AD among the common causes of death with heart disease, cancer and stroke (Kung, 
Hoyert, Xu & Murphy, 2008).  This disease manifests itself through impaired memory and 
decline in other related cognitive faculties, namely: aphasia (impairment of language and 
interpretation), apraxia (loss of different motor skills), agnosia (impairment in object 
recognition), and executive functioning (Diagnostic and Statistical Manual of Mental Disorders, 
text revision [DSM-IV-TR]; American Psychiatric Association, 2000; Tariot, Profenno, & Ismail, 
2004). 
There is now a consensus on the aetiology of AD as the last century had advances in the 
neurosciences, immunohistochemistry methods and brain imaging techniques (Cummings & 
Zhong, 2006). The amyloid cascade hypothesis suggests that there is an accumulation of beta-
amyloid (Aβ) that is either caused by the overproduction and abnormal processing of amyloid 
precursor protein (APP) or by the inability to clear the expressed Aβ, resulting in amyloid plaque 
deposition. This results in a cascade of secondary actions that finally result in the cognitive and 
behavioural phenotypes of dementia (Cummings, Vinters, Cole & Khachaturian, 1998). 
A variety of coexisting psychiatric symptoms have been reported in individuals with AD, 
including depression and anxiety. Dementia occurs in up to 20 percent of individuals diagnosed 
with anxiety disorders (Chemerinski, Petracca, Manes, Leiguarda, & Starkstein, 1998; Ferretti, 
McCurry, Logsdon, Gibbons, & Teri, 2001; Forsell & Windblad, 1997; Skoog, Nilsson, 
Palmertz, Andreasson & Svanborg, 1993; Starkstein, Jorge, Petracca, & Robinson, 2007). 
Further, about 70 percent of patients with dementia suffer from symptoms of anxiety (Ballard, 
Neil, O’brien, McKeith, Ince, & Perry, 2000; Chemerinski et al., 1998; Cummings & Back, 
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1998; Lyketsos, Breitner & Rabins, 2001; Wands et al., 1990). More than half of all AD patients 
show symptoms of apathy, agitation, depression, anxiety and aberrant motor behaviours 
(Cummings, 2006). Such reports suggest that anxiety and other non-cognitive behaviours have a 
serious impact on a larger proportion of patients with AD. 
In conjunction with advances in our understanding of the neurobiological basis of AD, 
there is evidence to suggest the neurobiological basis for the behavioural and psychological 
symptoms of dementia (BPSD). Functional neuroimaging studies have demonstrated the 
relationship of BPSD to the parietal lobe in anxiety and depression, and the frontal and temporal 
lobes in agitation and psychosis (Sultzer, 1996). Cell loss in the locus coeruleus, a major nucleus 
for secreting neuroepinephrine, is linked to depression (Bondareff, 1996; Lyketsos et al. 2000), 
and downregulation of serotonin, norepinephrine and dopamine levels in the brain stem, 
midbrain, and limbic regions (including the amygdala and the hippocampus) are associated with 
anxiety and depression (Dunlop, & Nemeroff, 2007; Lyketsos et al. 2000; Marin, 1991; Ressler, 
& Nemeroff, 2000). In AD, gene polymorphisms of the serotonin receptor 5-HT2C and the 
serotonin transporter have been implicated in psychosis and agitation (Assal et al. 2004; Holmes, 
Arranz, Powell, Collier, Lovestone, 1998; Nacmias et al., 2001). This further emphasizes the 
necessity of studying BPSD and the associated brain regions affected in AD (Cummings & 
Zhong, 2006).  
The symptoms of dementia in AD extend beyond memory impairment. As the disease 
progresses, the BPSD become more apparent (Cantillon et al., 1997; Scharre & Chang, 2002; 
Wragg & Jeste, 1989), and have a major impact on the patient’s cognitive processes (Tariot et 
al., 2004). There is a direct relationship between the symptoms of anxiety and dementia. 
Seignourel, Kunik, Snow, Wilson, and Stanley (2008) reported that, depending on the brain 
regions that are affected, neurodegeneration will not only lead to the cognitive impairments 
associated with the neocortex, as extensively studied, but also will lead to behaviours associated 
with pathological changes in the limbic structures. Moreover, anxiety is more evident in patients 
affected by dementia in comparison to the rest of the geriatric population. Finally, there exists an 
overlap between the symptoms of anxiety and the symptoms of dementia (Seignourel et al., 
2008). These observations emphasize the importance of studying the relationship between 
cognitive decline and anxiety in patients with AD. 
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Until recently, very few studies have investigated the relationship of anxiety and 
dementia. For instance, Starkstein et al. (2007) investigated generalized anxiety disorder (GAD) 
among one hundred and forty-four patients with AD, and found that “restlessness, irritability, 
muscle tension, fears, and respiratory symptoms in the context of excessive anxiety and worry” 
(p. 45), were valid symptoms for predicting GAD in AD. This is the first documented study that 
empirically clarifies the clinical presence of GAD in patients with AD. The criteria that 
Starkstein et al. measured specifically imply the need for examining the relationship between 
anxiety and memory in AD in order to ascertain appropriate treatment for these behaviour 
changes.  
To date, atypical antipsychotics are the most promising and popular form of treatment 
used to control the BPSD in AD. Studies have demonstrated the effectiveness of atypical 
antipsychotics for treating cognitive impairment, and protecting neurons from dying (Carson, 
McDonagh & Peterson, 2006), and more recently BPSD (Rocca, Marino, Montemagni, Perrone, 
& Bogetto, 2007). Atypical antipsychotics, including quetiapine, are used in treating patients 
with BPSD such as psychoses, aggression and agitation (Caballero, Hitchcock, Scharre, 
Beversdorf & Nahata, 2006; Scharre & Chang, 2002; Street et al., 2000). Despite adverse effects 
such as increased risk of cerebrovascular events, sedation, increased body mass index, and death, 
Schneider et al. (2006) reported that quetiapine was the most effective atypical neuroleptic for 
specifically treating anxiety, psychoses, and mild cognitive impairments. These studies provide 
evidence for the potential of quetiapine in treating AD patients. 
Familial Alzheimer’s disease (FAD) can be described as an AD phenotype that occurs in 
two or more family members, with or without known genetic causes. Twenty-five percent of all 
AD cases are of the FAD type (Bird, 2008). Bird also found that six percent of all AD cases are 
early-onset (EO), and approximately 60% of all EO (<60 years) cases are FAD, with 13% 
inherited in an autosomal dominant pattern. The discovery of genes involved in FAD, in which 
APP and the presenilins account for about 5% of all AD cases (Tanzi & Bertram, 2005), led to 
the development of transgenic animal models of AD. These transgenic models are widely used in 
studying drug effects as well as gene function in AD. One transgenic animal model is based on 
the observation that types of FAD are associated with the overexpression of APP found on 
chromosome 21, or mutations in the presenilin 1 and presenilin 2 genes found on chromosomes 
14 and 1, respectively. The transgenic animal model incorporating both the human APP and PS1 
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genes exhibits high levels of Aβ42(40) and Aβ plaques, which are not normally found in mice. A 
transgenic mouse model that incorporates APP and PS1 genes offer an opportunity to study 
reliably the AD pathology as well as drug treatments that are involved in AD.  
 
1.1 Neurobiological/Neuropsychological Basis of Alzheimer’s Disease: Amyloid Cascade 
Hypothesis 
 
AD, a neurodegenerative disease associated with cognitive decline, as well as psychiatric 
and behavioural complications (Cantillon et al., 1998; Scharre & Chang, 2002; Wragg & Jeste, 
1989), affects approximately 2% of the population in industrialized countries 
(http://www.alz.org), and is characterized by biochemical and pathological abnormalities, such 
as cerebral amyloid plaques, neurofibrillary tangles, and synaptic and neuronal loss in the brain. 
A pathological hallmark of AD is the formation of amyloid plaques, in which Aβ is a major 
component (Storey & Cappai, 1999; Suh & Checler, 2002; Van Gassen & Annaert, 2003). Aβ is 
derived through the abnormal processing of the larger transmembrane amyloid precursor protein 
(APP) by two enzymes: β-secretase (β-site APP-cleaving enzyme, BACE) and a presenilin (PS)-
dependent γ-secretase complex (Fukumoto et al., 2004; Lazarov et al., 2005), while α-secretase 
cleaves the Aβ sequence itself and is usually considered as nonamyloidogenic (Wilquet & De 
Strooper, 2004). β-Secretase mediates the initial step of Aβ production by β-cleavage of APP, 
and β-secretase inhibitors reduce Aβ production in APP transgenic mice (Asai et al., 2006). Aβ 
load is correlated with increased β-secretase expression and enzymatic activity in sporadic 
Alzheimer’s disease patients (Li et al., 2004; Yang et al., 2003). Together, these changes result in 
a cascade of secondary actions, including the hyperphosphorylation of tau protein and the 
development of neurofibrillary tangles, as well as free radical formation causing oxidative stress 
which damages and kills neurons. In addition, the neurons respond to the injury by microglial 
activation and cytokine production resulting in inflammation. Together, the excess of oxidative 
stress and excitotoxicity will lead to apoptosis and cell death (Hardy & Selkoe, 2002). As a result 
of this, the loss of neurons produces deficiencies in neurotransmitters, notably acetylcholine, 
serotonin, and noradrenaline. Finally, the loss of neurons results in the cognitive and behavioural 
phenotypes of dementia (Cummings et al., 1998). Increased brain Aβ levels and/or Aβ plaques 
may be the primary influence resulting in neuronal degeneration in AD (Hardy & Selkoe), in the 
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impairment of long-term potentiation in APP/PS1 transgenic mice (Chapman et al., 1999), and 
the inflammatory responses in transgenic models of AD (Matsuoka et al., 2001). 
In both clinical and animal studies, findings have indicated two very different outcomes 
in levels of Brain-derived neurotrophic factor (BDNF) in the hippocampus and cortex. BDNF is 
a 27-kDa homodimeric protein that plays an important role in differentiation, growth, repair, cell 
survival and neurogenesis. The first report of changes in BDNF expression in AD was in 1991. 
Phillips et al. (1991) found that BDNF mRNA levels were decreased in the hippocampus of AD 
patients, and the decreased expression of BDNF may be related to the neuronal cell death and 
cognitive impairment. Further studies found reductions in pro-form of BDNF (or premature 
BDNF), and mRNA transcripts in the parietal cortex of AD post-mortem brains (Fahnestock, 
Garzon, Holsinger, & Michalski, 2002; Garzon Yu, & Fahnestock, 2002; Holsinger, Schnarr, 
Henry, Castelo, & Fahnestock, 2000; Michalski & Fahnestock, 2003). In animal models of AD, 
the conclusions have been conflicting. Szapacs, Numis & Andrews (2004) found in a APP/PS1 
Tg2576 (Swe) model of AD a progressive increase in the expression of BDNF in 12 (70%) and 
18 (170%) month old mice. The authors concluded that the early increases in BDNF may play a 
compensatory mechanism in response to neuronal degeneration associated with Aβ deposition. In 
another study, BDNF was decreased in three diferent mouse models of AD (Fahnestock, Garzon, 
Peng, Flood, Salehi & Mount, 2006). The most striking decrease was in the CRND8 strain, 
where BDNF mRNA levels were reduced by 41% in 12 month-old CRND8, but BDNF was also 
reduced in 18 month old APP and APP/PS1 Tg2576 (Swe) mice. They concluded that 
overexpression of APP alone was sufficient to down-regulate BDNF mRNA in cortical tissue of 
AD transgenic mice (Fahnestock et al., 2006). These studies illustrate that a reduction in BDNF 
levels is associated with increases in amyloid plaques in the AD brain (Burbach et al.,2004; 
Ferrer et al., 1999; Murer et al., 1999). This suggests a relationship between BDNF alterations in 
the hippocampus and cortex, and cognitive dysfunction. It is still unknown whether changes in 
BDNF levels can be found in other brain structures of AD patients such as the amygdala.  
 
1.2 Potential Factors Involved in Anxiety and Alzheimer’s Disease 
 
The following sections compare and contrast studies that investigate the implications of 
behaviours in AD and the neural circuits responsible for mediating anxiety in rat and mouse 
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models. Furthermore, this review section assesses studies regarding the neuronal basis of 
maladaptive anxiety and the implications of this on memory loss. Molecular circuitries involved 
are also presented. 
 
1.2.1 Anxiety 
 
Anxiety is an adaptive emotion that prepares individuals to face and cope with potentially 
dangerous environmental situations (Gross, 1999). Anxiety is accompanied by behavioural and 
physiological responses that enable an individual to escape from danger or to avoid a potentially 
dangerous situation in the future (Livesey, 1986). Pathological anxiety as defined by the DSM-
IV-TR (2000) as uncontrollable and excessive anxiety and worry (apprehensive expectation), for 
at least six months, that manifests itself in various symptoms of anxiety disorders. In GAD, the 
most common type of anxiety, symptoms include feelings of restlessness and fatigue, difficulty 
in concentrating, irritability, muscle tension and sleep disturbances (DSM-IV-TR). In simple 
terms, pathological anxiety is inappropriate, uncontrollable maladaptive physiological and 
behavioural responses accompanied by high sympathetic activity that persistently and 
excessively interfere with daily living activities in physical and social settings (Ohl, Arndt & van 
der Staay, 2008).  
Pathological anxiety in humans may differ from that in animals, in that in humans there is 
a sense of apprehensive expectation without physiological arousal. Although it is currently 
impossible to detect apprehensive expectation in animals, comparable behavioural and 
physiological patterns of adaptive anxiety exist in animals and humans humans (Hall, 1936; 
Lang, Davis, & Ohman, 2000). Such behaviours include freezing, autonomic changes, startle, 
hypoalgesia, and increased urination and defecation. The neural pathways of anxiety control 
include the subcortical regions notably the amygdala that activates the hypothalamus which in 
turn activates the sympathetic system and the hypothalamic-pituitary-adrenal axis and modulates 
higher levels of neuronal processing (Catherall, 2003; Davis, 1998).  
The difference between pathological anxiety (maladaptive) and anxiety (adaptive 
anxiety) is that anxiety is characterized by an adaptive response to an imminent threat. However, 
when anxiety circuits are overactivated, because of maladaptive behaviours or neurobiological 
changes, this may lead to hyperexcitable anxiety circuits that may transform normal anxiety into 
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pathological anxiety (Eysenck, 1992; Mathews & MacLeod, 1994). Ultimately, the anxiety 
circuits become more sensitive and independent from the original triggering stimuli, and no 
longer under conscious control. In turn, the hippocampus and cortex modulate the lower levels of 
neuronal processing (Catherall, 2003; Davis, 1998). Anxiety increases attention and sharpens 
risk assessment. However, risk assessment may become impaired in times of excessive anxiety if 
the hippocampus becomes over-activated, causing disturbed cognitive processing and abnormal 
inhibitory behaviours. 
 
1.2.2 Clinical Anxiety in Alzheimer’s Disease 
 
Although pathological anxiety is fundamentally maladaptive, a considerable amount of 
distress can be present without any apparent changes in behaviour (Handley, 1995). Normal 
anxiety, on the other hand, is an adaptive response, which functions to protect individuals from 
threat and harmful situations. Few studies have investigated the relationship between the BPSD 
and cognitive impairment, and those that have been done produced inconsistent findings 
regarding this relationship (Cummings, Schneider, Tariot, Kershaw & Yuan, 2004). Anxiety 
alone causes a significant burden on the quality of life of the individual limiting activities of 
daily living, triggering sudden awakenings during sleep and impairing neuropsychological 
performance, without being affected by symptoms of depression (Hoe, Hancock, Livingston, & 
Orrell, 2006; McCurry, Gibbons, Logsdon, & Teri, 2004; Starkstein et al., 2007). A positive 
correlation exists between anxiety in dementia and future nursing home placement (Logsdon, 
Gibbons, McCurry & Teri, 2002). 
Regarding demographic and socio-environmental factors, current data suggest that there 
is no relationship between sex, age, or education and the risk of developing anxiety in AD 
(Ballard, Boyle, Bowler & Lindesay 1996; Ballard et al. 2000; Hwang, Masterman, Ortiz,  
Fairbanks, & Cummings, 2004; Katona & Shankar, 1999; Mendez et al., 2006; Orrell & 
Bebbington, 1996; Ownby, Hardwood, Barker, & Duara, 2000; Paulsen, Ready, Hamilton, 
Mega, & Cummings, 2001). However, anxiety appears to be more prevalent in Hispanics and 
Asians affected with dementia, than in those with Black or Caucasian origins (Chen, Borson, & 
Scanlan, 2000; Ortiz, Fitten, Cummings, Hwang, & Fonseca, 2006). Thus far, studies have 
suggested that anxiety is relatively stable as the disease progresses until the terminal stage, when 
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it suddenly decreases (Chen, et al., 2000; Sclan, Saillon, Franssen, & Hugonot-Diener, 1996). 
However, it is possible that caregivers and clinicians may not be able to identify the symptoms 
because they rely heavily on verbal and motor abilities for identifying the anxiety state of the 
patient (Aalten, van Valen, Clare, Kenny, & Verhey, 2005). It is possible that patients unable to 
verbalize may still experience anxiety that goes unnoticed by caregivers and clinicians.  
Studies have explored the mechanism through which changes in behaviour relate to 
cognitive impairment. In animals however, only a few studies have examined the effects of 
quetiapine in animal models of AD. Using the object recognition task, He et al. (2004), 
demonstrated in our laboratory (lab) that quetiapine prevented methamphetamine-induced 
memory impairment and neurodegeneration. In addition to this study, He and colleagues (2005a) 
in our lab, reported that chronic administration of quetiapine reduced anxiety-like behaviours 
caused by dl-amphetamine in rats.  
 
1.2.3 Cognition and Anxiety 
 
Cognition and anxiety together form highly complex phenomena that regulate basic 
survival instincts (Clement and Chapouthier, 1998). The worries, disturbing thoughts, and 
abnormal information processing are difficult to assess in animals at this point in time (McNally, 
1998). However, there exists a relationship between cognitive processes and anxiety, and it may 
be that cognitive distortions are at the root of pathological anxiety (Beuzen and Belzung, 1995; 
McNaughton, 1997; Hindmarch, 1998). It has been argued that anxiety is the result of a gap 
between newly perceived information and stored information (Gray, 1990). Further, it may be 
that GAD is the result of cognitive impairment causing inappropriate emotional responses 
(McNaughton, 1997). In turn, anxiety can influence affective and declarative memories (Cahill 
and McGaugh, 1998; McNaughton, 1997).  
Conditioned anxiety may increase sensitivity to internal and external stimuli, and 
sometimes can enhance cognitive performance (Battaglia and Ogliari, 2005; Ohl et al., 2003). 
However, pathological anxiety can impair adaptive responses in stressful situations. An 
individual’s response to anxiety is dependent on cognition, and previously stored experiences are 
used as a reference point to compare current external and internal stimuli. Therefore, there is a 
link between the awareness of cognitive impairments and the symptoms of anxiety in dementia 
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(Aalten, van Valen, Clare, Kenny, & Verhey, 2005). The anxiety in dementia patients may be 
due in part to the awareness of one’s cognitive decline and anxiety of it (Aalten, van Valen, 
Clare, Kenny, & Verhey, 2005; Mintzer et al., 2000). In later stages, the aetiology of anxiety in 
dementia becomes more complex; it is precisely the preserved verbal abilities that permit the 
expression of the awareness of the deficits and anxiety. 
 
1.3 The Neurobiological/Neuropsychological Basis of Anxiety 
 
1.3.1 Anxiety Circuit 
 
Rosen and Schulkin (1998) reviewed studies that focused on the neural pathways 
involved in anxiety and provided an explanation of how the amygdala plays a key role in normal 
and pathological anxiety. Projections from the medial portion of the geniculate nucleus, posterior 
intralaminar nucleus, suprageniculate nucleus, and temporal auditory and perirhinal cortices are 
linked directly to the lateral nucleus of the amygdala carrying auditory conditioned stimuli 
(Burwell, Witter, & Amaral, 1995; LeDoux, Farb, & Ruggiero, 1990; LeDoux, Sakaguchi, & 
Reis, 1984; MacDonald & Jackson, 1987; Romanski & LeDoux, 1993; Suzuki, 1996). The 
perirhinal cortex projecting to the lateral nucleus also participates in visual conditioned stimuli 
(Campeau & Davis, 1995b; Coordimas & LeDoux, 1995; Rosen, Hitchcock, et al., 1992). The 
basolateral nucleus receives projections from the hippocampus via the ventral subiculum 
(Canteras & Swanson, 1992) and has apparent involvement in anxiety conditioning (Maren & 
Fanselow, 1996). In understanding the relationship of anxiety to Alzheimer’s disease, it is 
essential to study the amygdala, which is the core of the anxiety circuitry. 
 
1.3.2 Amygdala 
 
The amygdala is a fundamental neuronal structure because it is involved in emotional 
responses linked to novel stimuli as well as to learned stimuli. In relation to anxiety, this 
neuronal structure has numerous projections, particularly to the hippocampus, the cortex and the 
hypothalamus. For instance, as anticipatory anxiety regulation is influenced by the amygdala, the 
hypothalamus is linked to reactive and homeostatic anxiety regulation (Beaulieu, DiPaolo, Cote, 
 10 
 
& Barden, 1987; LeDoux, Iwata, Cicchetti, & Reis, 1988) while the frontal cortex plays a role in 
the extinction of behaviour to fearful stimuli (Morgan, Romanski, & LeDoux, 1993). In relation 
to the amygdala, the hippocampus plays a role in context-specific processing of fearful 
information (Kim & Fanselow, 1992; Phillips & LeDoux, 1992). Overall, the amygdala works to 
assess and integrate predictable as well as unpredictable information from the internal and 
external environment in order to adapt and produce appropriate responses to changing 
environmental situations (Richardson, 1973; 1974; 1993).   
The amygdala plays a key role in normal and pathological anxiety and other emotional 
and cognitive activities. Psychosocial stressors initiate changes in the cortico-amygdala circuitry 
and hyperexcitability of this circuitry is triggered through a neural sensitization process, which 
can also be modeled by kindling, a process in which the brain of an animal repeatedly stimulated 
electrically or chemically, develops seizures. Kindling amplifies an animal’s perception and 
response of an imminent threat and danger. During anxiety, there is an increased release of 
glucocorticoids, which increase the corticotrophin-releasing hormone in the amygdala and the 
extended amygdala. Excitation of the amygdala and the extended amygdala, notably the bed 
nucleus of the stria terminalis (BNST), plays a major role in attention and arousal in response to 
anxiogenic stimuli. The amygdala and the BNST are critical for specific and nonspecific 
pathological anxiety (Davis, Walker, & Lee, 1997). The amygdala is involved in computing 
sensory and autonomic information into psychological and behavioural responses (Aggleton & 
Mishkin, 1986; LeDoux, Cicchetti, Xagoraris, & Romanski, 1990). More specifically, the central 
nucleus of the amygdala is involved in the output pathway and activates physiological, 
autonomic, and behavioural responses (Iwata, Chida, & LeDoux, 1987; Kapp, Gallagher, 
Underwood, McNall, & Whitehorn, 1982; Rosen & Davis, 1988a). 
The central nucleus and other parts of the amygdala, such as the lateral and basolateral 
nuclei, are involved in anxiety-induced physiological responses. Such responses include 
bradycardia, changes in respiration, freezing, startle, and analgesia (Campeau & Davis, 1995; 
LeDoux et al., 1990; Roozendaal et al., 1990; Sananes & Davis, 1992; Iwata et al., 1987; Rosen 
& Davis, 1988a). The central nucleus also receives autonomic information from the brain stem 
nuclei; including the dorsal motor nucleus of the vagus, lateral hypothalamus, and the 
parabrachial nucleus, that control physiological responses (Koh & Ricardo, 1978; Veening, 
1978). It is also worth noting that the sensory, auditory and nociceptive information from 
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subcortical regions also act on the central, lateral, and basolateral nuclei of the amygdala 
(Aggleton & Mishkin, 1986; Bernard, Alden, & Besson, 1993; LeDoux, et al., 1990; LeDoux, 
Sakaguchi, & Reis, 1984; Turner & Herkenham, 1991). Moreover, neurons of the lateral nucleus 
respond to conditioned anxiety stimuli (Quirk, Repa, & LeDoux, 1995). Lesions in the lateral 
amygdala (LA) produced severe impairment of conditioned anxiety; whereas, the basolateral 
nuclei was associated with aversive memories (Maren, Aharonov, & Fanselow, 1996; Parent, 
West, & McGaugh, 1994). Lesions in the basolateral amygdala (BLA) produced severe 
impairment of aversive memory linked to anxiety (Maren, Aharonov, & Fanselow, 1996; Parent, 
West, & McGaugh, 1994). These findings suggest the involvement of the basolateral nuclei in 
anxiety and memory loss, topics that warrant further attention in behavioural research in AD.  
Anxiety and pathological anxiety may be under the control of the BNST (Davis et al., 
1997). The brainstem projections of the BNST innervate many of the same structures as the 
central nucleus of the amygdala (Alheid et al., 1995; Wallace, Magnuson, & Gray, 1992). Davis 
and colleagues investigated whether the BNST differentiates between anxiety (nonspecific 
stimulus) induced and anxiety (stimulus-specific) induced using the light enhanced startle reflex 
(Davis et al.). The authors concluded that the BNST was implicated in anxiety whilst the central 
nucleus was more involved in stimulus-specific anxiety response. In addition, in Hitchcock & 
Davis’s 1991 study, the basolateral amygdala was involved in both specific and nonspecific 
stimuli responses. Interestingly, the molecular consequences of hyperexcitability, resulting from 
either long-term potentiation (LTP) or the early stages of kindling may induce the cascade of 
genetic events involved in the production of BDNF (Ou & Gean, 2007). The altered expression 
of BDNF is related to cognitive impairment and anxiety-like behaviour.  
Low levels of BDNF protein in the hippocampus and the amygdala are associated with 
increased anxiety-like behaviours (Chen et al., 2006). In 2004, Rattiner and colleagues’ genetic 
studies confirmed the relationship of BDNF in the BLA as they demonstrated that BDNF gene 
expression is increased in the BLA during acquisition of new memory in the fear potentiated 
startle (FPS) behavioural testing (Rattiner et al., 2004a). In addition, the tyrosine kinase B 
receptor in the amygdala is critical for the acquisition of conditioned anxiety (Rattiner et al., 
2004a). Overall, these studies have strong implications for investigating BDNF changes in the 
BLA when studying anxiety in mouse models. 
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Küçük, Gölgeli, Saraymen, & Koç (2008) suggested that decreased BDNF in the BLA 
may be associated with memory impairment. 
1.3.3 Hippocampus 
These authors highlighted the signal cascades 
linking the initial physiological events by which fear conditioning modulates the expression of 
BDNF in the lateral amygdala. These authors suggest that calcium influx through N-methyl-D-
aspartate (NMDA) receptors and L-type voltage-dependent calcium channels (L-VDCCs) during 
fear conditioning activates cAMP-dependent protein kinase (PKA) and calcium/calmodulin- 
dependent kinase IV (CaMKIV) resulting in cAMP response element binding protein (CREB) 
phosphorylation (Monfils, Cowansage & Ledoux, 2007; Ou & Gean, 2007). The phosphorylated 
CREB binds to BDNF promoters I and III, and up-regulates the expression of BDNF in the LA, 
which helps the consolidation of fear memory (Figure 1). The diagram illustrates the molecular 
cascade that leads to BDNF increase in the amygdala.  
 
 
Numerous studies regarding the relationship between the hippocampus and cognitive 
functions have been published, but even though the hippocampus plays important roles in 
emotion responses, there are very few publications concerning the hippocampus and anxiety. 
Intrahippocampal infusion studies in animals support a distinctive role of the hippocampus in 
anxiety. Notably, gamma-aminobutyric acid (GABA) type A receptor agonists, glutamate 
antagonists, serotonin antagonists and acetylcholine esterase inhibitors have reliable anxiolytic 
effects (Alves, Pinheiro, Motta, Landeira-Fernandez & Cruz, 2004; Degroot, Kashluba & Treit, 
2001; Degroot and Treit 2002; Gonzalez, Ouagazzal, File 1998; Hackl & Carobrez 2006; Nunes-
de-souza, Canto-de-Souza & Rodgers 2002; Rezayat, Roohbakhsh, Zarrindast, Massoudi & 
Djahanguiri, 2005). The hippocampus, according to the Papez model (1937), acts as a relay 
center between the cingulate cortex and the hypothalamus, facilitating emotional experience and 
expression respectively. Later, MacLean's (1949) theory explained that the hippocampus is the 
central area through which emotion-related stimuli act by filtering information to other limbic 
systems, such as the amygdala. In relation to anxiety, the hippocampus and the septum represent 
the control for behaviour inhibition (Gray, 1982). Conversely, LeDoux (2000) argued that 
anxiety itself, and more specifically conditioned anxiety, is linked to the amygdala, suggesting 
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that the hippocampus possesses a limited role as it simply codes contextual cues associated with 
anxiety. 
Comparatively, a similar argument was presented by Davidson and Jarrard (2004), who 
showed that the hippocampus performs the function of associative/inhibitory conditioning in 
anxiety. Presumably, the hippocampus can be divided into two parts, the dorsal and the ventral 
regions, in which the dorsal is mainly involved in memory and learning, and the ventral mainly 
in anxiety (Bannerman et al., 2004). Studies remain inconclusive as to the dissociation of the 
hippocampal roles in anxiety and memory. This leaves the opportunity for further studies to 
investigate the underlying mechanisms between anxiety and memory.  
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Figure 2. Diagram of the signal cascades linking the initial physiological events by which 
fear conditioning modulates the expression of BDNF in the lateral amygdala (LA).  
Calcium influx activates cAMP-dependent protein kinase (PKA) and calcium/calmodulin- 
dependent kinase IV (CaMKIV) which phosphorylates cAMP response element binding protein 
(CREB). Phosphorylated CREB binds to BDNF promoters I and III, and up-regulates the 
expression of BDNF in the LA. This results in the consolidation of fear memory. (Monfils, 
Cowansage & Ledoux, 2007).  
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1.3.4 Serotonin 
 
The monoamine neurotransmitter serotonin (5-HT) plays an important role in the 
pathophysiology and treatment of anxiety disorders (Baldwin, Anderson, Nutt, Bandelow, Bond, 
Davidson, den Boer, Fineberg, Knapp, Scott & Wittchen, 2005). Increased serotonergic 
neurotransmission induces anxiety-like behaviours in animals and in humans (Cloninger, 1987; 
den Boer, Westenberg, De Leeuw & van Vliet, 1995; Griebel, 1995; Handley, 1995; Plomin, 
Owen, & McGuffin, 1994). Evidence of hyperactivity of the serotonergic system causing 
anxiety-like behaviours also comes from studies of the 5-HT1A receptors (5-HT1AR). Martin & 
Humphrey (1994) reviewed the literature regarding the identification and cloning of the 5-HT 
receptor subtypes (5-HT1, 5-HT2, 5-HT3). The 5-HT1AR has received the most attention 
because of the availability 5-HT1AR agonists such as busprione or 8-OH-DPAT, and because of 
the importance of this receptor in relation to anxiety (Coplan, Wolk & Klein, 1995; Murphy, 
1990). 5-HT1A receptors are coupled to G-proteins and are negatively coupled to adenylyl 
cyclase (Hoyer & Schoeffter, 1991; Julius, 1991). 5-HT1AR are presynaptic inhibitory 
autoreceptors as well as postsynaptic receptors (De Vry, 1995). Activation of 5-HT1AR 
decreases the firing rate of serotonergic neurons (Blier, de Montigny & Tardif, 1987; Jolas et al., 
1993; Sprouse & Aghajanian, 1988). 
 Recently, Nash et al. (2008) measured in patients with panic disorder (PD), the receptor 
binding capabilities using a single positron emission computed tomography (SPECT) 5-HT1A 
tracer [11C]WAY-100635. The 5-HT1A receptors are located both presynaptically and 
postsynaptically. The 5-HT1A receptors were located in the different brain regions using a 
previously validated database (Rabiner et al., 2002), and by hand for the raphé nuclei (Nash et 
al.). Nash et al. used the parametric binding-potential and took the mean voxel value to calculate 
the regional binding potential values. In the amygdala, orbitofrontal cortex and temporal lobe 
postsynaptic receptors have been associated with a decrease in anxiety. In the raphé nuclei 
presynaptic 5-HT1A receptors have also been associated with decreased anxiety. Both 
presynaptic and postsynaptic 5-HT1A receptor binding was reduced in the amygdala, 
orbitofrontal cortex, temporal cortex, and raphé nuclei of untreated PD patients in comparison to 
healthy volunteers. Lanzenberger et al. (2007) found that patients with social anxiety disorder 
had lower levels of 5-HT1A binding in the amygdala and anterior cingulate cortex as revealed by 
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[11
 The expression of 5-HT1A receptors in the hippocampus and cortex during the first two 
postnatal weeks is critical for the development of anxiety-like behaviour in adulthood (Lidov & 
Molliver, 1982; Gross et al., 2002). Serotonin levels in the postnatal period also influence long-
lasting changes in brain plasticity in visual and sensory cortices and the dentate gyrus (Cases et 
al., 1996; Upton et al., 1999; Haring & Yan, 1999), and the 5-HT1AR may be a critical mediator 
of the developmental effects of serotonin. Yan, Wilson & Haring (1997) found a depletion in the 
dendritic spine density of the dentate gyrus, after treatment with a 5-HT1AR antagonist (NAN-
190). Gross et al. showed that expressing 5-HT1AR, primarily in the hippocampus and cortex, is 
sufficient to create a normal anxiety phenotype in 5-HT1AR knockout mice. They used a double 
transgenic mouse model carrying a rescuable knockout allele of the 5-HT1AR crossed with a 
transgenic mouse carrying the bacterial tTA protein under the control of the α-calcium-
calmodulin-dependent protein kinase II (αCaMKII) promoter to achieve expression of the 5-
HT1AR in a tissue-specific and temporally controlled manner. Essentially, this 5-HT1AR-
αCaMKII complex is critical as it produces a cascade of events leading to prolonged changes in 
the brain chemistry, thus playing an important role in the development of normal anxiety-related 
behaviour. In brief, evidence from studies on postnatal development, spine density, or knockout 
C]WAY-100635. In anxiety disorders, such as in panic disorder or social anxiety SPECT 
studies have shown the reduced binding of 5-HT1A receptors, indicating that the 5-HT1A 
receptors are a valid target in finding new and improved treatments for anxiety disorders. 
Previous studies with 5-HT1AR knockout mice found an increase in serotonin 
neurotransmission in the dorsal raphé nuclei, hippocampus, and to a lesser extent in the cortex, 
and an increase in anxiety-like behaviours in the open-field test and the Porsolt forced swim test 
(Parks, Robinson, Sibille, Shenk & Toth, 1998). The 5-HT1AR can affect other 
neurotransmitters including dopamine (DA) and noradrenaline (NA). The medial prefrontal 
cortex 5-HT1AR increase the DA release in the ventral tegmental and the mesocortical areas 
(Díaz-Mataix et al., 2005). Atypical antipsychotics may elevate the extracellular levels of DA 
through this mechanism. The stimulation of 5-HT1ARs in the dorsal raphé nucleus induces a 
decreased NA release from the locus coeruleus (Pudovkina, Cremers & Westerink, 2002). 
Increased 5-HT1AR firing caused by acute immobilization leads to raised NA release in the 
hippocampus (Rioja et al., 2007). Overall, studies show that anxiety is related to elevated levels 
of serotonin neurotransmission —most notably through the 5-HT1AR.  
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model describe the importance of the 5-HT1AR in the hippocampus and corteces in the 
development of the phenotype of anxiety. 
 
1.3.5 Avoidance and Escape 
 
All forms of anxiety can be categorized into two main types: conditioned anxiety also 
known as avoidance, and unconditioned anxiety also known as escape. Studies investigating the 
neurobiological basis of avoidance have revealed the specific connections involved in each type. 
An identifiable region associated with avoidance that can be studied clearly in the mouse is the 
BLA. For instance, projections from the BLA to the striatum are related to avoidance behaviour 
(Everitt & Robbins, 1992). In addition, BLA projections to the forebrain may be involved in 
attention and vigilance (Gallagher & Holland, 1994). An even higher-order region of control 
involved in this context-specific process is the prefrontal cortex. Here, the prefrontal cortex is 
involved in behaviour extinction in relation to conditioned anxiety (Gray & McNaughton, 1996). 
These areas should be studied in future investigations.  
There has also been an accumulation of evidence that supports the importance of the 
central nucleus of the amygdala in avoidance behaviour. Information pertaining to anxiety and 
anxiety-related stimuli, travel either directly to the central nucleus, or go through the basolateral 
nucleus before arriving at the central nucleus of the amygdala (Pitkanen et al., 1995; Stefanacci 
et al., 1992). The basolateral nucleus projections to the lateral BNST may also be involved in 
avoidance behaviour (Davis, et al., 1997; Deasy, Shi, & Davis, 1997). Overall, both the central 
nucleus of the amygdala and the lateral BNST project through the ventral amygdalofugal 
pathway directly to many diencephalic, midbrain, and brain stem structures. Evidence also 
suggests that the hippocampus plays a role in context-specific processing of anxiety-related 
information (Kim & Fanselow, 1992; Phillips & LeDoux, 1992). Risk assessment and 
behavioural inhibition are main responses that occur and are associated with the 
septohippocampal region (Gray & McNaughton, 1996). 
The second form of anxiety, unconditioned anxiety, can be described as the desire to 
escape from a threatening dangerous or unpleasant environment. It is also important to 
understand the neurobiological basis of escape in an effort to differentiate pathways involved in 
conditioned anxiety or avoidance. The periaqueductal gray plays a central role as an output 
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pathway in escape behaviour (Bandler & Shipley, 1994; Carrive, 1993; Fanselow, 1994). The 
stimuli that activate the nucleus reticularis pontis caudalis create a startle response in rodents 
(Davis, Gendelman, Tischler, & Gendelman, 1982; Lee, Lopez, Meloni, & Davis, 1996), where 
input from the central nucleus of the amygdala boosts the startle response (Rosen & Davis, 
1988b, 1990; Rosen et al., 1991). An important target region of the central nucleus of the 
amygdala is the periaqueductal gray in the midbrain that controls defensive behaviours, such as 
escape (Bandler & Shipley, 1994; Fanselow, 1994; Hostege, 1995). Studies that investigate 
anxiogenic changes should differentiate the neurobiological pathways involved in avoidance 
from those involved in escape. 
 
1.4 APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease 
1.4.1 Relevance of Transgenic Mouse Studies to Clinical Trials 
 
Further evidence of the neurobiology of AD comes from animal models based on the 
genetics linked with FAD patients. The understanding of the genes involved in FAD has 
provided us with a useful model in studying the various aspects of the disorder. Transgenic 
mouse models of AD are based on mutations found in FAD patients’ genes, particularly APP or 
the genes coding for the presenilin (PS) enzymes PS1 and PS2. Games et al. (1995) constructed a 
PDAPP V717F transgenic mouse model that developed Aβ plaque depositions in the brain 
comparable to those of AD patients. These mice overexpressed a mutated form of human APP 
that resulted in an Aβ load by 6 months, and by 18 months in mild deposits in the walls of the 
blood vessels of the brain comparable to the cerebral amyloid angiopathy (CAA) observed in AD 
patients. Hsiao et al. (1996) published a report describing a convincing mouse model of AD. 
These authors created a Tg2576 transgenic mouse line carrying a human APP complementary 
DNA with double Swedish mutation (K670N and M671L) under the control of hamster prion 
protein promoter (PRP). Heterozygous Tg2576 mice produced APP 5.5-fold over wild type 
endogenous levels and developed diffuse and neuritic plaques in the hippocampus, cortex, 
subiculum, and cerebellum at around 9 to 11 months of age. These pathological changes result in 
memory deficits in mice as observed in the water maze test that are comparable to the memory 
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deficits seen in patients with AD. CAA is practically non-existent in these mice at 18 months of 
age (Hsiao et al., 1996).  
Currently most studies investigating treatment for AD use the PDAPP or the Tg2576 
mouse lines. Other models in this category include the APP23 (K670N/M671N), which produces 
higher levels of human APP than does the Tg2576 (Sturchler-Pierrat, 1997). Also, the TgCRND8 
mouse affects both β-secretase and γ- secretase activities, and has a very aggressive rate of Aβ 
deposition because it carries both the Indiana (V717F) and the Swedish (K670N/M671L) 
mutations (Chishti et al., 2001). While the APP: V717I mouse carries a different APP mutation, 
it closely resembles the PDAPP mouse (Moechars et al., 1999). The first mouse model to 
produce the tau pathology is the APP23 (Calhoun, 1998). These APP23 transgenic mice 
upregulate APP, increase hyperphosphorylation of tau, and produce mild cortical neuronal loss.  
Ultimately, these transgenic mouse models of AD provide researchers with opportunities to test 
and discover the underlying mechanisms of therapeutic agents involved in treating the symptoms 
associated with AD. 
The double transgenic mouse model of AD produced by crossing mice expressing the 
M146L mutation in PS1 with Tg2576 mice markedly accelerates the rate of Aβ deposition in the 
brain and produces more of the fibrillogenic Aβ1-42 species (Holcomb et al., 1998). Mice with 
single mutations in PS1 do not express the Aβ plaques until many months later (Duff et al., 
1996). Newer AD mouse models have introduced mutations in tau protein. The discovery that 
mutated tau protein is involved in frontotemporal dementia (FTD) has lead to the development of 
a mutated tau transgenic animal model. Lewis et al. (2000) created the JNPL3 mouse, the first 
transgenic mouse model to incorporate a tau mutation, the human tau P301L. The JNPL3 mouse 
develops hyperphosphorylation of tau protein in the dendrites and soma of neurons, which results 
in the formation of neurofibrillary tangles (Lewis et al., 2000). Oddo et al. (2003) created a triple 
transgenic, 3XTg mouse model of AD. This model carries APP (Swedish, Tg2576), PS1 
(M146L), and tau (P301L) human mutations, and these mice express significant intracellular Aβ 
and hyperphosphorylated tau, and extracellular Aβ deposits (Oddo et al., 2003). However, 
stereological methods demonstrated no significant loss of neurons (Oddo et al. 2003). Several 
other transgenic mouse models of AD also show promise. Capsoni et al. (2000) created a mouse 
model expressing recombinant antibodies blocking nerve growth factors causing both Aβ 
plaques and tau pathology.  
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Recently, Colton et al. (2006) created a mouse model combining APP (Tg2576) with a 
nitric oxide synthase 2 knock-out, which produces Aβ plaques, hyperphosphorylated tau, and 
neuronal loss. Finally, a model of vascular dementia, APPSwDI (K670M/N671L, E693Q, and 
D694N), shows a rapid progression of Aβ deposition particularly associated with the vasculature 
(Davis, 2004). However, what is fascinating about this model is that it has a deficiency in the 
clearance of Aβ across the blood-brain barrier (Davis, 2006). This is one of the very first models 
to actually mimic the lack of clearance of Aβ from the brain similar to that seen in CAA patients. 
Some of the functional disruptions in the Tg2576 mouse include impairment of LTP, 
synaptic disruption, dystrophic neurites and gliosis in the hippocampus and in the cortex. The 
overexpression of human APP clearly accounts for much of the Aβ pathology. As demonstrated 
in the Y-maze and Morris Water maze, APP transgenic mice have significant cognitive 
impairment (He et al., 2007). However, APP mutations are only part of the AD puzzle as 
presenilins also play an important role in FAD. In 1996, Duff and collaborators constructed mice 
expressing the mutant presenilin genes. The mutant presenilins act in a dominant fashion in mice 
expressing the PS1 transgene, and selectively increase Aβ42(43) levels. As described earlier, the 
interaction of presenilins and APP encourage the formation of fibrillogenic plaques, by altering 
the processing of APP. Crossing Tg2576 mice with PS1 M146L mice significantly increases 
Aβ42(40) levels and accelerates the deposition of Aβ plaques compared with single transgenic 
mice Tg2576 (Hsiao et al., 1996; Games et al., 1995; Holcomb et al., 1998; Sturchler-Pierrat et 
al., 1997). Transgenic animals currently available are reliable, valid and highly useful models for 
studying diseases such as AD and for providing insight into the pathogenesis and potential 
pharmacological treatments of AD. 
  
1.4.2 Anxiety-Like Behaviour in APP/PS1 
 
A review of the literature shows that there exists a number of conflicting findings 
regarding the APP/PS1 and the phenotype of their anxiety-like behaviours. For instance, in one 
study using single transgenes, Ognibene et al. (2005) showed that mice overexpressing APP, 
such as APP23 (APP751) and Tg2576 (APP695), either show no change or a distinct reduction 
in anxiety in the elevated plus maze (EPM). Contrary to Ognibene et al. (2005), Lee et al. (2004) 
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reported that mice expressing the Swe/Indiana mutated APP exhibit increased anxiety levels and 
microarray analysis revealed altered gene expression by more than two folds in the amygdala. 
The expressions of tumor necrosis factor-α, T-LAK, cell-originated protein kinase, 
hematopoietic-cell specific Lyn susbtrate 1, calmodulin 4, and transthyretin were increased by 13 
months of age; whereas X (inactive)-specific transcript, chemokine (C-C motif) ligand 6, and 
cullin 4B were decreased. However, single transgenes may not be appropriate models of AD. 
Arendash et al. (2001) found no significant changes in anxiety levels of APP/PS1 when tested in 
the EPM. Furthermore, findings by Jensen et al. (2005) support decreased levels of anxiety in the 
APP/PS1 on the EPM. Despite the use of double transgenes, neither Arendash et al. (2001) nor 
Jensen et al. (2005) found increased levels of anxiety elicited by the EPM, but a recent study by 
Pugh et al. (2007) demonstrated increased levels of anxiety in the APP/PS1 mouse model of AD 
that was associated with the onset of the neuropathology and the Aβ plaque deposition. Our AD 
model (He et al., 2007), carrying APP and PS1 mutated genes, not only showed accelerated AD-
like plaque load and memory impairment, but also increased anxiety-like behaviours.  
 
1.5 Behavioural Testing: The Elevated T Maze 
1.5.1 Overview of the Elevated T-Maze (ETM) 
 
As it is recognized that anxiety is comprised of various types of clinical manifestations 
(DSM-IV, TR, 2000), it is imperative that measures of anxiety show specificity in accordance to 
the type being studied. The elevated T-maze (ETM), a derivative of the elevated plus-maze 
(EPM), is exemplary in its inherent ability to produce robust measures of anxiety in mice 
(Jardim, Nogueira, Graeff & Nunes-de-Souza, 1999). The ETM was developed on the hypothesis 
that conditioned and unconditioned responses of anxiety can be separately measured in rats 
(Zangrossi & Graeff, 1997). Zangrossi and Graeff found that conditioned anxiety, or inhibitory 
avoidance, appears to be related to GAD-like behaviours, whereas unconditioned anxiety, or 
one-way escape, appears to be related to PD-like behaviours.  
Physically, the ETM apparatus is a simple design. It is composed of three arms of equal 
dimensions, elevated 50 cm above the ground. One of these arms is enclosed, for the purpose of 
concealing the rodent’s vision from the perpendicular arms until it has passed the lateral walls. 
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Inhibitory avoidance is measured as the mean latency for the rodent to leave the enclosed arm 
and enter the open arms in three consecutive trials. One-way escape is measured as the mean 
latency of the rodent to escape from the open arms and enter into the closed arm, again in three 
consecutive trials. The observations that occur are that the rodent learns to avoid the open arms 
when repeatedly placed inside the enclosed arm. When the rodent is placed at the end of the open 
arm it escapes and rapidly enters the closed arm. Therefore, inhibitory avoidance represents 
learned anxiety or conditioned response, while escape represents innate anxiety or unconditioned 
response. It is suggested that the ‘openness’ is the main factor motivating both inhibitory 
avoidance and one-way escape in the ETM (Zangrossi & Graeff; 1997). 
The efficacy of the elevated T-maze (ETM) as a model of anxiety and memory was first 
documented in a study by Graeff, Viana & Tomaz (1993) using rats (see also De-Mello & 
Carobrez, 2002; Viana et al., 1994), and was later empirically supported by evidence of 
ethological validity of the apparatus for use with mice (Carvalho-Netto & Nunes-de-Souza, 
2004; Jardim, Nogueira, Graeff & Nunes-de-Souza,1999; Zangrossi & Graeff, 1997). The 
presence of the open and enclosed arms at an elevated level in the ETM model is its ethological 
hallmark feature because they reliably elicit natural anxiety among rodents. In other words, a 
rodent’s presence on the open arm of an elevated maze is an unpleasant and rather maladaptive 
experience (Treit et al., 1993). Such a circumstance is readily controlled in a lab setting because 
it naturally induces anxiety. Inhibitory avoidance and one-way escape in the ETM both result 
from the openness in this maze. The repeated exposure to the ETM induces the mice to learn an 
inhibitory (passive) avoidance of the open arms (i.e. increased latencies to leave the enclosed 
arm over three consecutive trials) which is comparable to the anxiety that mice would experience 
in the wild when they encounter heights and open spaces (Graeff, Netto & Zangrossi, 1998). In 
lab studies, the acquisition of inhibitory avoidance is long-lasting, even 120 days after the 
training period; the rodents still avoid the open arms (Sanson & Carobrez, 1999). This test is 
based on the natural aversion of rodents towards a novel open and elevated, and potentially 
dangerous area.  
Torrejais et al. (2008) used multivariate methods to assess the specificity of anxiety 
measures for PD-like and GAD-like behaviours. The results from factor analyses not only 
supported the heterogeneity of anxiety, revealing various types,  but also the validity of the ETM 
in evoking expressions of both PD-like and GAD-like behaviour depending on the procedure 
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used. Such studies indicate that the ETM is useful in assessing different sub-types of anxiety in 
mice.  
 
1.5.2 Pharmacological Studies Using the ETM 
 
Due to the reliability as well as construct and ethological validity of the ETM for eliciting 
anxiety in rodents, pharmacological studies of drug treatment for anxiety can capitalize on the 
ETM as well. The significance of the ETM as a function of specific anxiety measures is that the 
effectiveness of anxiety-related drug treatments can be tested. There is an extensive literature 
based on using the ETM for pharmacological studies of the acute and chronic effects of 
conventional anxiolytics given to humans for GAD and PD. As previously mentioned, GAD is 
an anxiety disorder that is characterized by inappropriate, excessive, uncontrollable and often 
irrational worry (DSM-IV-TR, 2000). Panic Disorder, classed as an anxiety disorder, is 
characterized by recurring brief, inappropriate and unpredictable periods of extreme anxiety. 
Typically these attacks last about ten to twenty minutes and are accompanied by exaggerated 
symptoms of anxiety such as excessive perspiration, dizziness, airway constriction, trembling, 
tachycardia, hyperventilation, uncontrollable fear, derealization, depersonalization (DSM-IV-
TR). Studies in ETM have shown that acute administration of diazepam, buspirone or ritanserin, 
selectively impairs inhibitory avoidance acquisition (IAA) yet does not affect escape (Graeff, 
Netto & Zangrossi, 1998; Pinheiro, Zangrossi, Del-Ben & Graeff, 2007). In contrast, escape in 
the ETM is impaired only by chronic treatment with panicolytic agents, namely imipramine and 
fluoxetine (Poltronieri, Zangrossi & Viana, 2003; Teixeira, Zangrossi & Graeff, 2000). Clinical 
observations have shown that GAD is responsive to most tricyclic antidepressants (TCA), 
selective serotonin reuptake inhibitors (SSRI), benzodiazepines, buspirone and ritanserin. 
Whereas, PD is unresponsive to most benzodiazepines, buspirone and ritanserin. Moreover, PD 
is best overcome by chronic treatment with panicolytic agents including imipramine and 
fluoxetine (Ballenger, 1993; Liebowitz, 1989; Nutt, 1991; Sheehan, 1999; Pollack et al., 1996).  
Evidence from the use of the ETM in pharmacological studies shows differing effects of 
two classes of anxiolytics. Benzodiazepine receptor agonists, such as diazepam, and 5-HT1A 
agonists, such as buspirone, impair inhibitory avoidance while leaving escape performance 
unaffected (Graeff et al., 1993; Viana et al., 1994; Graeff et al., 1998). These pharmacological 
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results suggest that inhibitory avoidance is related to GAD. In contrast, escape performance is 
impaired only by chronic administration of drugs such as imipramine (Teixeira et al., 2000), 
clomipramine or fluoxetine (Poltronieri et al., 2003), which are used to treat PD. Drugs acting on 
serotonergic receptors in the dorsal raphé nucleus such as kainic acid, and D-fenfluramine 
facilitate avoidance and impair the one-way escape behaviours in the ETM (Graeff, Viana & 
Mora, 1996). These studies of anxiety using mice and the ETM provide further evidence 
consistent with the ETM eliciting two specific types of anxiety, as well as evidence for effective 
drug treatment for PD-like and GAD-like anxiety.  
Acute injection of sibutramine decreased inhibitory and one-way escape in the ETM 
(Jorge, Pobbe, Soare, Oliveira & Zangrossi, 2004), while buspirone impaired the inhibitory 
avoidance, but had no effect on the one-way escape. This differentiation of drug treatment on the 
two specific types of anxiety warrant further attention to the underlying mechanisms through 
which the drugs actually produce their effect. It is possible that other factors related to brain 
function, may be involved in the selectivity of drug response to conditioned versus 
unconditioned anxiety. Overall, this pharmacological profile supports the view that ETM 
generates GAD-like and PD-like behaviours in not only the rat but also the mouse (Jardim, 
Nogueira, Graeff & Nunes-de-Souza, 1999).  
 Gomes et al (2009) investigated the effects of acute (a single intraperitoneal injection 30 
min before testing) and chronic (daily i.p. injections for 15 consecutive days) treatment with 
imipramine and fluoxetine, on inhibitory avoidance and one-way escape of mice in the ETM. 
Acute fluoxetine (0, 5, 10, 20 or 40 mg/kg, i.p.) treatment increased the inhibitory avoidance and 
decreased the open arm withdrawal, whilst chronic treatment (0, 5, 20 or 40 mg/kg, i.p.) 
decreased the inhibitory avoidance acquisition and increased the escape latency. On the other 
hand, neither acute nor chronic treatment with imipramine (0, 1, 5 or 10 mg/kg, i.p.) had an 
effect on the behaviour of mice in the two ETM tasks. These results suggest that inhibitory 
avoidance acquisition is a useful task for the evaluation of acute and chronic effects of anxiolytic 
treatment on anxiety in mice. 
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1.5.3 Neuronal Connectivity and Anxiety 
 
Studies have found that the ablation of the amygdala or hippocampus reduces passive 
avoidance of the open arms in the ETM indicating a reduction in anxious behaviour or perhaps 
impaired memory associated with anxiety (Coover, Trivedi & Heldt, 2002; Trivedi, Heldt & 
Coover, 2004). Viana and colleagues’ (2008) publication revealed activation of 5-HT1A 
receptors of the lateral septum (LS), a region with a high density of these receptors, is implicated 
in inhibitory avoidance as well as one-way escape in the ETM. This finding suggests that 5-
HT1A activity in the LS may be involved in the neurobiology of anxiety. The effects of 8-OH-
DPAT, a 5-HT1A and 5-HT7 agonist, were compared to the effects of the benzodiazepine 
receptor agonist midazolam (MDZ, 20 nmol) (Viana, et al., 2008). Also the administration of 
intra-LS injection of the 5-HT1A receptor antagonist WAY-100635 (0.37 nmol) was able to 
block the effects of 8-OH-DPAT. Results revealed that whereas intra-LS administration of MDZ 
decreased avoidance latencies, suggesting an anxiolytic action, 8-OH-DPAT caused increased 
avoidance, suggesting an anxiogenic action. Neither drug affected the escape performance. Intra-
LS administration of WAY-100635 blocked the anxiogenic effect caused by 8-OH-DPAT. This 
is evidence that LS 5-HT1A receptors are involved in inhibitory avoidance and a malfunction of 
this mechanism shares a relationship with the mechanism of action of GAD (Viana, et al., 2008). 
Duzzioni et al. (2008) investigated the relationship between substance P (SP), an agonist 
of NK1, and diazepam (DZP) in the modulation of anxiety and memory in rats in the ETM, and 
found that pretreatment with DZP (1mg/kg, i.p.) significantly decreased the latency of the rats to 
leave the enclosed arm of the ETM. However, DZP did not decrease the latency of the rats to 
leave the enclosed arm when SP was pre-administered (10 pmol, i.c.v.). This maladaptive 
behaviour was interpreted as representing both an anxiolytic, in the test period, as well as 
amnesic outcome, in the re-test periods. Their study also showed an interaction between the 
tachykinergic and benzodiazepine–GABA systems in the modulation of anxiety. SP may block 
the anxiolytic effects produced by DZP. Furthermore, in 2003 Strauss et al. reported that the 
amygdala plays a critical role in the modulation of anxiety. After male rats had received bilateral 
N-methyl-D-aspartate (NMDA)-induced lesions of the amygdala, they were tested on the ETM, 
2, 7, or 14 days later. They found that the inhibitory avoidance was impaired for 14 days after the 
procedure. These findings reflect anxiolytic effects due to the lesions in the animal’s amygdala. 
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Particularly relevant to the present study, Tomaz et al. (1991) have shown that large 
NMDA-induced lesions of the amygdala impaired, but did not block, acquisition of inhibitory 
avoidance, thus suggesting that other brain structures are also involved in the acquisition of this 
behavioural response. A possible candidate is the hippocampus. Trivedi and Coover (2004) 
studied the effect of electrolytic lesions of the dorsal and ventral hippocampus on locomotor 
activity and on anxiety-like behaviour in the ETM. Lesions in the ventral hippocampus reduced 
the latency to emerge from the enclosed arm on trials 2 and 3 of the ETM, and again, no effect 
was observed in the one-way escape. The ventral hippocampus may be specifically involved in 
modulating conditioned anxiety and memory aversive experience related to the open arms; 
through hypothalamic and amygdaloid connections. Furthermore, Treit and Menard (1997) have 
shown that bilateral electrolytic lesions of the amygdala or the hippocampus, but not of the 
septum, caused a distinct and selective impairment of inhibitory avoidance. On the other hand, 
lesions of the septum increased open arm exploration in the elevated-plus maze (EPM) whereas 
lesions of the amygdala or the hippocampus had no effect. Together, these results led the authors 
to propose that the amygdala and the hippocampus may be part of a pathway specialized for 
passive avoidance of painful or anxiety-inducing stimuli. Lesions appeared to be mainly 
concentrated in the lateral, basolateral, and basomedial nuclei. This opens the opportunity for 
future studies to investigate these neuronal regions and their implications in anxiety. 
 
1.6 Quetiapine’s Effect in Alzheimer’s Disease 
1.6.1 Atypical Antipsychotics 
 
Antipsychotic drugs having therapeutic efficacy in treating schizophrenia are divided into 
two groups, typical (conventional) and atypical (novel). Typical antipsychotics, represented by 
chlorpromazine and haloperidol, ameliorate only the positive symptoms. Atypical antipsychotics, 
including clozapine, olanzapine, quetiapine, and risperidone, are effective in treating the positive, 
negative, and cognitive symptoms, and have a low association with dyskinesia or parkinsonism 
(Velligan et al., 2002; Purdon, Malla, Labelle & Lit, 2001; Beasley, Tollefson & Tran, 1997; 
Cuesta, Peralta, & Zarzuela, 2001; Jann, 2004). Clinical studies have found atypical 
antipsychotics to be effective in the treatment of a wide range of neuropsychiatric conditions, 
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including depressive symptoms associated with psychotic and mood disorders (Brugue & Vieta, 
2007), posttraumatic stress disorder (Pae et al., 2008), and psychosis in Alzheimer’s disease 
(Madhusoodanan, Shah, Brenner & Gupta, 2007). Olanzapine, quetiapine, and risperidone have 
beneficial effects on neurocognitive functioning in patients with early psychosis (Keefe et al., 
2007), and quetiapine also improves psychotic symptoms and cognition in Parkinson’s disease 
without worsening motor symptoms (Juncos et al., 2004). 
Both typical and atypical antipsychotics bind to dopamine receptors, and the blockade 
of dopamine D2 receptors in the mesolimbic region is thought to be the mechanism responsible 
for the reversal of positive symptoms by antipsychotics (Wong & Van Tol, 2003). Atypical 
antipsychotics also bind to serotonin (5-HT) receptors. The different affinities of antipsychotics 
for brain dopamine D2 and 5-HT2A receptors may be helpful in understanding some of the 
different therapeutic effects of atypical antipsychotics (Kapur, Zipursky & Remington, 1999; 
Seeman & Tallerico, 1999). However, the mechanisms underlying their therapeutic effects on 
negative and cognitive symptoms of schizophrenia may go beyond the dopamine and serotonin 
receptor blockade effects, this requires further investigation.  
Neuroanatomical and clinical studies of schizophrenia suggest that progressive 
neuropathological changes, such as neuronal atrophy and/or cell death, occur over the course of 
the disease (Woods, Yurgelun-Todd, Benes, Frankenburg, Pope & McSparren, 1990; 
Waddington, O'Callaghan, Buckley, Larkin, Redmond, Stack & Ennis, 1991; DeLisi, Sakuma, 
Tew, Kushner, Hoff & Grimson, 1997; Arnold & Trojanowski, 1996). Cognitive deficits tend to 
occur early in the course of schizophrenia, and the severity of deficits is predictive of the social 
and occupational functioning as well as the long-term treatment outcome for patients (Green, 
1996). Neural injury or neurodegeneration may cause cognitive deficits in schizophrenia 
(Harvey, 1998). Therefore, the beneficial effects of atypical antipsychotics on behaviour may be 
related to their possible effects on neuroprotection and/or neurogenesis beyond the dopamine and 
serotonin receptor blockade effects.  
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1.6.2 Neuroprotective Properties of Quetiapine and Other Atypical Antipsychotics 
 
Quetiapine (Seroquel®) is an atypical antipsychotic drug possessing properties that have 
an effect on an array of psychotic and mood disorders (data on file, AstraZeneca 
Pharmaceuticals, Wilmington, DE, USA). For instance, this drug has been shown to effectively 
alleviate positive and negative symptoms, as well as cognitive impairment, in schizophrenia 
patients (Velligan et al., 2002; Velligan, Prihoda, Sui, Ritch, Maples & Miller, 2003; Purdon et 
al., 2001). Quetiapine has been used effectively in the treatment of schizophrenia since 1997 
(Srisurapanont et al 2004), and of manic episodes of bipolar disorder since 2003 (Berk & Dodd 
2005; Calabrese et al., 2005; Croissant et al., 2006). Quetiapine is also approved for the 
treatment of patients’ depressive disorder (Todder et al., 2006; Baune et al., 2007). Preliminary 
evidence suggests a role for quetiapine in managing symptoms of anxiety in bipolar disorder 
(Hirschfeld et al., 2006). 
 Studies have demonstrated that quetiapine seems to work by targeting dopamine and 
serotonin neurotransmission in the pre-frontal cortex, striatum, limbic system, and anterior 
pituitary (data on file, AstraZeneca Pharmaceuticals, Wilmington, DE, USA; Jensen et al., 2008). 
Quetiapine is a dibenzothiazepine derivative that has a greater affinity for serotonin 5-HT2 
receptors than dopamine D2 receptors, together with considerable activity at histamine H1 
receptors, and at α1- and α2-adrenergic receptors. Studies have concluded that quetiapine is a 
competitive antagonist at D2 and 5-HT2 receptors, and acts as a partial agonist at 5-HT1A 
receptors (Jensen et al., 2008; Arango & Bernardo, 2005; Todder et al., 2006; Dannlowski et al., 
in press).  Evidence from clinical studies has demonstrated the effectiveness of atypical 
antipsychotics in treating the psychotic symptoms associated with dementia (Tariot, 2004).  
Quetiapine is considered to be very effective in treating patients with dementia, not only because 
of its low propensity for extrapyramidal symptoms, but also for treating a range of BPSD 
symptoms. 
 In animal studies, quetiapine attenuates the methamphetamine-induced neurotoxicity and 
memory impairment (He et al., 2004; He, Yang, Yu, Li, & Li, 2006b), alleviates the 
amphetamine-induced anxiety-like behaviours (He, Xu, Yang, Zhang, & Li, 2005a), and 
counteracts the phencyclidine-induced reference memory impairment and decreased Bcl-XL/Bax 
ratio in the cortex of rats (He, Xu, Yang, Rajakumar, Li, & Li, 2006a). In a clinical study, 
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quetiapine was shown to improve psychotic symptoms and cognition in Parkinson’s disease 
(Juncos et al., 2004). In addition, quetiapine effectively alleviated psychoses in AD, but its 
possible beneficial effects on cognition in AD remain uncertain (Scharre & Chang, 2002; 
Caballero et al., 2006). This uncertainty of quetiapine’s effect on cognition implies that future 
studies should investigate whether quetiapine has beneficial effects on cognitive impairment in 
AD and acts as a neuroprotectant in treating its pathological changes. 
Atypical antipsychotics increases the levels of BDNF, an important neurotrophin mainly 
expressed and distributed in brain neurons (Xu et al., 2002). Neurotrophins are growth factors 
that act directly on neurons to support their growth, differentiation, and survival (Yuen and 
Mobley, 1996). Xu and colleagues (2002) documented that quetiapine attenuated the 
immobilization stress-induced decrease in BDNF expression in the rat hippocampus. Later 
studies concluded that atypical antipsychotics also modulated the level of other growth factors, 
such as fibroblast growth factor 2 (FGF-2) and nerve growth factor (NGF), that may play 
important roles in changing synaptic plasticity, normalizing cognitive deficits, and preventing 
cell degeneration (Parikh, Evans, Khan & Mahadik, 2003; Fumagalli et al., 2004). Building upon 
these findings, other studies were able to demonstrate that atypical antipsychotics increased the 
level of Bcl-2 and modulated the Bcl-XL/Bax ratio in the brain. Bcl-2, a neuroprotective protein, 
inhibited apoptosis by sequestering proforms of death-driving caspases and preventing the 
release of mitochondrial apoptotic factors into the cytoplasm (Adams & Cory, 1998; Bai, Zhang 
& Li, 2004; Bruckheimer, Cho, Sarkiss, Herrmann & McDonnell, 1998). The mRNA and protein 
expression of Bcl-2 in rat frontal cortex and hippocampus were increased after chronic atypical 
antipsychotic treatment (Bai et al., 2004). In addition, olanzapine drug treatment prevented 
methamphetamine-induced Bcl-2 decrease and accelerated the restoration of Bcl-2 in 
hippocampal neurons from the repeated restraint stress-induced decrease (He, et al., 2004; Luo, 
Xu & Li, 2005).  Furthermore, in their study, Wei, Mousseau and colleagues (2003) reported that 
atypical antipsychotics attenuated neurotoxicity of β-amyloid by modulating Bax and Bcl-XL/S 
expression and localization in PC12 cells.  In addition, He, Xu and colleagues (2006) revealed 
that quetiapine attenuated the phencyclidine-induced decrease in the Bcl-XL/Bax ratio in the 
posterior cingulate cortex in rats. In vivo studies have demonstrated the neuroprotective 
properties of quetiapine and other atypical antipsychotics, particularly through the modulation of 
growth factors and inhibiting apoptosis. 
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In in vitro studies, quetiapine was effective in reducing PC12 cell death induced by serum 
withdrawal or by oxidative stress induced by hydrogen peroxide, β-amyloid peptide, or MPP+ 
(Bai et al., 2002; Qing, Xu, Wei, Gibson & Li, 2003; Wei, Bai, Richardson, Mousseau & Li, 
2003; Wei, Mousseau, Richardson, Dyck & Li , 2003). Atypical antipsychotics have antioxidant 
properties. Studies were able to demonstrate that clozapine, olanzapine, quetiapine, and 
risperidone increased the gene expression of superoxide dismutase (SOD1) in PC12 cells, and 
prevented cell death after serum withdrawal (Bai et al., 2002; Li et al., 1999). Atypical 
antipsychotics may have a common antioxidant action that would be responsible for their 
cytoprotective effects in reducing PC12 cell death induced by serum withdrawal or by the 
addition of hydrogen peroxide, β-amyloid peptide, or MPP+ (Bai et al., 2002; Qing et al., 2003; 
Wei, Bai et al., 2003; Wei, Mousseau et al., 2003). 
1.6.3 Neurogenesis, Atypical Antipsychotics and Alzheimer’s disease 
Olanzapine and quetiapine prevented PC12 
cells from Aβ-induced apoptosis and the overproduction of intracellular reactive oxygen species, 
attenuated Aβ-induced activity changes of the antioxidant enzymes (SOD1, catalase, and 
glutathione peroxidase), and blocked Aβ-induced decrease in mitochondrial membrane potential 
in PC12 cells (Wang, Xu, Dyck, & Li, 2005). In a clinical study atypical antipsychotics also 
induced other neuroprotective effects, such as olanzapine’s effect of increasing gray matter 
volume and reducing symptoms of psychopathology in schizophrenia (Lieberman et al., 2005). 
Overall, in vitro studies suggest the neuroprotective effects of atypical antipsychotics may be 
explained in part by their antioxidant properties. 
 
 
Neurogenesis, or neuronal regeneration, is a process of producing new functionally 
integrated neurons from progenitor cells (Ming & Song, 2005). Atypical antipsychotics increase 
cell proliferation and neurogenesis in adult rat brain (Kodama, Fujioka & Duman, 2004; 
Wakade, Mahadik, Waller & Chiu, 2002). Although the function of neurogenesis in the 
hippocampus of the APP/PS1 mouse model is unknown, clinical evidence also supports the 
importance of the formation of new neurons in the hippocampus (Roy et al., 2000). The 
formation of some types of memory relies on the continuous production of new hippocampal 
neurons throughout adulthood (Bruel-Jungerman, Rampon & Laroche, 2007). Therefore, it is 
 31 
 
possible that the beneficial effects of atypical antipsychotics on learning and memory may be 
linked to their up-regulation of neurogenesis. 
The hippocampus may be unique, in that it continues to produce new neurons 
throughout life, and this may be enhanced in AD (Verret, Jankowsky, Xu, Borchelt & Rampon, 
2007). Targeting neurogenesis in the hippocampus may be a potential therapy for delaying or 
reversing the progression of AD. Postmortem brain studies in AD patients show increased 
hippocampal neurogenesis in the DG and CA1 (Jin et al., 2004), consistent with our recent 
findings in the APP/PS1 (Yu et al., in press). Neurogenesis can be found throughout adulthood in 
the brain (Lie, Song, Colamarino, Ming & Gage, 2004), and can be further stimulated by 
neuropathological conditions. Neurogenesis was increased in the dentate gyrus after transient 
global ischemia in gerbils (Liu et al., 1998), in the hippocampus of rodents in an epilepsy model 
(Parent et al., 1997), and in the adult human Huntington’s disease brain (Curtis et al., 2003). The 
increased neurogenesis observed in AD may be a compensatory response to pathological and 
behavioural impairments.  
 
1.6.4 Atypical Antipsychotics Including Quetiapine: Effects in Alzheimer’s Disease and the 
APP/PS1 Transgenic Mouse Model 
 
Preliminary animal studies revealed that quetiapine and olanzapine expressed their 
neuroprotective properties when facing endogenous or exogenous insults. In rat studies chronic 
administration of quetiapine prevented the methamphetamine-induced recognition memory 
impairment and dopaminergic terminal loss (He et al., 2006), and alleviated the anxiety-like 
behaviours induced by a neurotoxic regimen of dl-amphetamine (He et al., 2005).  Similarily, 
mouse studies showed that quetiapine attenuated spatial memory impairment, depressive and 
anxiolytic-like behaviours, as well as hippocampal neurodegeneration in a global cerebral 
ischemia model (Yan, Bi et al., 2007; Yan, He et al., 2007). Zhang and colleagues (2008) also 
showed that quetiapine alleviated the cuprizone-induced white matter pathology in the brain of 
C57BL/6 mouse while Xiao and colleagues (2008) showed that quetiapine prevented myelin 
breakdown induced by cuprizone in mice. In studies of olanzapine in our lab, pretreatment of rats 
for 2 weeks with olanzapine prevented the methamphetamine-induced 24 h mortality and the 
decrease of immunoreactive tyrosine hydroxylase and Bcl-2 (an anti-apoptotic gene product) in 
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the caudate putamen (He et al., 2004). Olanzapine also attenuates the okadaic acid-induced 
spatial memory impairment and hippocampal cell death (He et al., 2005b).  
 
Quetiapine attenuated the memory impairment and the pathological changes in the 
APP/PS1 (He et al., 2007), reduced PC12 cell death and increased intracellular reactive oxygen 
species induced by Aβ(25-35) (Xu et al., 2008). These studies suggest that the anti-oxidant 
action of quetiapine may be useful in the treatment of AD.  Results from our lab suggested that 
quetiapine has preventive effects on memory impairment and pathological changes if given prior 
to the onset of the memory impairment and amyloid plaque deposition in the AD model (He et 
al.). Further, quetiapine may have beneficial effects on memory impairment and pathological 
changes when administered after the onset of memory impairment and amyloid plaque formation 
in the transgenic mouse model of AD. The long-term effects of quetiapine in AD can be clarified 
by future studies where the chronic administration of quetiapine begins in the early stages of AD. 
 
A recent study from our lab has shown that hippocampal neurogenesis was increased in 
the progressive stage of Alzheimer’s disease phenotype in the APP/PS1 mouse (Yu et al., in 
press). Bromodeoxyuridine labeling supported by doublecortin (DCX) staining was used to 
detect proliferating hippocampal neurons in these mice. Compared with age-matched wild-type 
controls, 9-month old transgenic mice had memory impairment, numerous brain Aβ deposits and 
an increased number of proliferating hippocampal neurons. This study suggests that hippocampal 
neurogenesis may increase during the progression of AD in humans. 
 
A number of studies have demonstrated the effectiveness of atypical antipsychotics, 
including quetiapine, in treating AD patients with BPSD such as psychoses, aggression and 
agitation (Caballero et al., 2006; Scharre & Chang, 2002; Street et al., 2000). Although 
quetiapine effectively alleviates psychoses in AD, its beneficial effects on cognition in AD 
remain inconclusive (Caballero et al.; Scharre and Chang). One possible reason for the uncertain 
effects of quetiapine on cognition is that the neuroprotective effects might be weakened or even 
lost with AD progression. Futher studies are necessary to examine quetiapine’s possible 
neuroprotective effects in AD.  
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On the other hand, despite adverse events such as increased risk of cerebrovascular 
events, sedation, increased BMI (Body Mass Index), and death from atypical antipsychotics in 
AD that Schneider et al. (2006) reported from their CATIE-AD study, quetiapine seemed most 
effective compared with other atypicals in specifically treating anxiety, psychoses, and cognitive   
disturbances. In 2006, a study by He, Xu et al. demonstrated the therapeutic effects of quetiapine 
on cognitive impairment and neurodegeneration. Quetiapine reduced the methamphetamine-
induced memory impairment in the object recognition task (He, Yang et al., 2006). Also, He, Xu 
et al. (2005) showed that chronic administration of quetiapine reduced anxiety-like behaviours in 
the light/dark box and in the open field tests caused by the neurotoxic doses of dl-amphetamine 
in rats. In a previous study by Xu et al. (2002), quetiapine was found to prevent the brain-derived 
neurotrophic factor (BDNF) decrease induced by chronic stress, in the rat hippocampus. The 
current state of quetiapine’s beneficial effects on anxiety-like behaviour remains unclear. 
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CHAPTER 2: METHODOLOGY 
 
2.1. Experimental Design 
2.1.1 General Hypothesis 
 
The present study was designed to examine anxiety-like behaviours in the 12-month old 
APP/PS1 double transgenic mice in comparison to non-transgenic controls, and to investigate the 
effects of quetiapine on these behaviours. In addition, this study measured BDNF levels in the 
amygdala. Two hypotheses will be addressed: (1) Quetiapine will reduce memory impairment, 
and anxiety-like behaviours; (2) Quetiapine will alleviate the BDNF decrease in the amygdala 
and hippocampus, and will reduce the plaque load in the hippocampus and cortex.  
 This study attempts to clarify the relationship between Aβ plaque load, memory 
impairment, and anxiety in a mouse model of AD. The expected findings are important because 
they may highlight the pathogenesis involved in AD as well as potential treatments for its 
symptoms. This study will not only contribute to the understanding of the relationship between 
BPSD and memory deficits in AD. It also has implications for early diagnoses and early 
intervention in AD patients, particularly because the animals in the current study begin to receive 
treatment before the onset of symptoms.  Lastly, the present study contributes to the field of AD 
research by addressing the underlying neurobiological effects of quetiapine on anxiety-like 
behaviours and BDNF in AD.  
 
2.1.2 Study Design Analysis 
 
This study was part of a larger study conducted in the laboratory.  The experiments 
included in this thesis used a 2 (transgene versus non-transgene (control) by 2 (quetiapine treated 
versus non-quetiapine treated (water) between subjects design.  Female and male animals that 
were control non-transgenic or transgenic were randomly assigned to either of 2 drug treatment 
groups, water or 5 mg/kg/day quetiapine. Animals received quetiapine treatment for 7 or 10 
months beginning at the age of 2 months old.  The study had 2 components:  animals were 
assessed on 2 measures of learning and memory and plaque load at the age of 9 months. Anxiety-
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like behaviour and BDNF were examined in other mice at the age of 12 months. A previous 
experiment in the laboratory found that anxiety was not as profoundly displayed at the age of 9 
months, so 12 month old mice were selected for the 2nd
Animals were assessed in 2 measures of anxiety in the ETM, escape and avoidance, and 
the brains were assessed for BDNF immunohistochemistry.  Another group of animals were 
examined on 2 measures of learning and memory, the Y-maze and the Morris Water Maze and 
the brains were assessed for plaque formation using Congo Red staining. 
 component of the study. 
For the learning and memory portion of the experiments and the corresponding plaque 
assessment, a 2.5 mg/kg/day quetiapine group was included because this was done early in the 
experiment series.  The 2.5 mg/kg/day group was subsequently excluded from the remaining 
studies because it was not different from the 5 mg/kg/day group.   
 
2.1.4 Animals 
 
All animal care and procedures with animals were performed in accordance with the 
guidelines established by the Canadian Council on Animal Care and were approved by the 
Animal Care Committee of the University of Saskatchewan. The APP/PS1 were generated from 
matings between APPK670N/M671L (Hsiao et al., 1996) and PS1M146L (Duff et al., 1996) 
(Figure 2). This model is recognized for exhibiting significantly increased Aβ42 and Aβ40 levels 
and accelerated deposition of Aβ plaques (He et al., 2007). In total, 118 female and 118 male 
mice were used in the present study (Table 1). The mice were individually implanted with a 
subcutaneous micro identification chip (BioMedic Data Systems Inc., Seaford, DE). Due to 
aggressive behaviour displayed between the male transgenic mice, all males were individually 
housed, while 4 to 5 female mice were housed in group cages. All mice received free access to 
food and water under controlled lab conditions (a 12:12 h light/dark cycle room temperature, 
20±1 ◦C), and were acclimatized for one week before the experiment.  
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Figure 3.PCR photographic representation of complementary DNA obtained from double 
transgenic APP/PS1 mouse carrier and single transgenic PS1 or APP mice carriers. 
Con: Control or non-transgenic; APP/PS1 Tg2576: Amyloid Precursor Protein and Presenilin 1 
M146L; APP: Amyloid Precursor Protein; PS1: Presenilin 1. 
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Table 1 
Number of Mice in Each Group. 
 
 
 Con Q2.5 Q5 Tg Tg+Q2.5 Tg+Q5 
9 month       
Male 13 8 14 14 8 16 
Female 8 9 7 8 7 9 
12 month       
Male 13 - 13 10 - 9 
Female 21 - 22 11 - 16 
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2.1.3 Drug Treatment 
 
Quetiapine was provided by AstraZeneca Pharmaceuticals (Macclesfield, UK). The mice 
were treated with quetiapine (5 mg/kg/day) orally in double distilled drinking water (2 mg/100 
mL water) for 10 months beginning at 2 months of age. The between group design was 
comprised of four groups: non-transgenic+water (Con), non-transgenic+quetiapine 5 mg/kg/day 
(Q5), transgenic+water (Tg), and transgenic+quetiapine (Tg+Q5). For selected experiments, an 
additional group of animals received 2.5 mg/kg/day of quetiapine for 7 months. In preliminary 
studies, there was no significant difference between the groups regarding the amount of water 
consumed per day. On average, a 30 g mouse drank 7.5 mL a day.   
 
2.2. Behavioural Testing 
 
Cognitive behaviours in the Y-maze and the Water-Maze were tested at 9 months of age 
and anxiety-like behaviours were tested in the ETM at 12 months of age.  
 
2.2.1 Anxiety: Elevated T-Maze 
 
The ETM (Viana, Tomaz & Graeff, 1994) is a T shaped wooden apparatus composed of 
3 arms with equal dimensions (50 × 12 cm) elevated at 50 cm above the floor (Figure 3). One of 
the arms is surrounded by three 20 cm high walls. To reduce the risk of mice falling off, the 2 
open arms are lined with a transparent plastic rim 5 mm high. To reduce additional stress in the 
testing environment, the experimenter observed and measured each mouse’s behaviour from 
outside of the procedural room using a camcorder that was suspended above the maze. 
Avoidance in the ETM is related to conditioned anxiety or GAD, and the one-way escape 
in the ETM is related to unconditioned anxiety or PD. At twenty-four hours preceding the 
behavioural testing, the mouse was habituated for 30 min to one of the open arms of the T-maze. 
On trial 1, the time taken by the mouse to leave the closed arm with all four paws was recorded 
as the baseline latency. The same measurement was repeated in two avoidance trials, avoidance 1 
and avoidance 2, at 30 sec intertrial intervals. After the avoidance phase the mouse was placed at 
 39 
 
the end of the open arm and the time to leave this arm with four paws was recorded as escape 
latency 1, 2 and 3, at a 30 sec intertrial interval. For each trial there was a cut off time of 300 sec 
(5 min), (Figure 4). For the ETM we used the 12 month old female (n=70) and male (n=45) 
mice. Table 1 illustrates the number of mice per group at 12 months of age.  
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Figure 4. Schematic representation of the elevated T-maze (ETM).  
The ETM is a T shaped wooden apparatus composed of 3 arms of equal dimensions (50 × 12 cm) 
elevated at 50 cm above the floor. One of the arms is enclosed by walls (20cm), and is 
perpendicular to the two arms. To reduce the mice from falling off, the 2 open arms are lined 
with a transparent plastic rim 5 mm high. 
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Figure 5. Model of the elevated T-maze (ETM) behavioural procedure.  
Twenty-four hours preceding the behavioural testing the mice were habituated for 30 min to one 
of the open arms in the T-maze. The time taken by the mouse to leave the closed arm on trial 1 
with all four paws was recorded as the baseline latency. The same measurement was repeated in 
two avoidance trials, Avoidance 1 and Avoidance 2, at 30 sec intertrial intervals.  After a 30 sec 
intertrial interval followed the one-way escape trials. The mouse was placed at the end of the 
open arm and the time to leave this arm with four paws was recorded as escape 1, 2 and 3. For 
each trial there was a cut off time of 300 sec (5 min).   
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2.2.2 Y-Maze Test  
 
Spatial working memory performance was assessed by a single trial recording 
spontaneous alternation behaviour in a 3 arm Y-maze (He et al., 2007). The Y-maze is based on 
the innate tendency of rodents to explore a novel environment, and measures spatial recognition. 
The memory performance on the Y-maze is often associated with the condition of the 
hippocampus and the effects of different treatments on the hippocampus and memory. The maze 
is made of painted black wood and the arms of the Y-maze are 35 cm long, 25 cm high and 10 
cm wide and are positioned at an equal angle from each other. The mice were individually placed 
at the end of one arm and allowed to move freely through the maze during an 8-min session. The 
ability to alternate requires that the mice know which arm they have already visited. The 
sequence of arm entries was recorded visually by an investigator. Spontaneous alternation 
behaviour was defined as the entry into all three arms on consecutive choices in overlapping 
triplet sets. The percentage of spontaneous alternation behaviour was calculated as the ratio of 
actual to possible alternations (defined as the total number of arm entries minus 2) multiplied by 
100. For the Y-maze we used the 9 month old female (n=48) and male (n=73) mice. Please refer 
to table 1 for the specific numbers of mice in each group at 9 months of age. 
 
2.2.3 Water Maze Test 
 
Spatial memory acquisition and retention by the mice were assessed with the Morris 
water maze (Morris, 1984). The Morris water maze is based on the innate tendency of rodents to 
escape a water filled area. It was developed by Richard Morris in (1984) and is commonly used 
today to explore the role of the hippocampus in the formation or acquisition and retention of 
spatial memory. This test was conducted on the day following the Y-maze test. The water maze 
consisted of a plastic pool (120 cm in diameter). An overhead video camera coupled to a 
computer with an image analyzer [Chromotrack (San Diego Instruments, San Diego, CA); 
EthoVision (Noldus Information Technology, Sterling, VA)] was used to track the movement of 
the mice (He et al., 2005a). In the acquisition (hidden-platform) phase, a hidden clear Plexiglas® 
platform (10 cm in diameter) was kept constant in the middle of one particular quadrant 
throughout training. The training consisted of 4 blocks of trials (4 trials/block, with a 5-min 
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intertrial interval). Each trial lasted until the mouse climbed onto the hidden platform or until the 
cut-off time of 60 seconds was elapsed.The time to find and climb on the platform was recorded 
as the escape latency. The retention (probe) test was carried out 24 hrs after the last training trial 
with the platform removed, each mouse was put into the pool for 60 sec, and the percentage (%) 
of time spent in each of the 4 quadrants was measured. For the Water maze we used the 9 month 
old female (n=48) and male (n=73) mice. Please refer to table 1 for the specific numbers of mice 
in each group at 9 months of age. 
 
2.3 Tissue Processing and Histology 
 
Following the behaviour tests, the mice were deeply anesthetized with Nembutal 
(50 mg/kg, i.p.), and perfused through the ascending aorta with 50 mL of 0.1 M phosphate-
buffered saline (PBS, PH 7.4). The left hemisphere was postfixed in 4% paraformaldehyde for 
24 hr followed by cryoprotection in 30% sucrose for 3 days. The left hemispheres of 12-month 
old mice were cut into 30-μm thick coronal sections, and a set of free-floating sections were used 
for BDNF immuno-histochemistry. The left hemispheres of 9-month old mice were cut into 30-
μm thick horizontal sections, and were used for Congo Red staining. The right hemispheres were 
used for other experiments.  
 
2.3.1 BDNF Level Measurements 
 
For BDNF immunohistochemistry, coronal sections were incubated with rabbit 
polyclonal anti-BDNF antibody (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA) for 12 h at 
4◦ C. The sections were then washed with phosphate-buffer containing 0.3% Triton X-100 and 
incubated with biotinylated goat anti-rabbit antibody (1:200; Biosource, Carlsbad, CA) at room 
temperature for 2 h. Finally, all sections were washed and processed with avidin-biotinylated 
horseradish peroxidase complex (Vector ABC kit, Vector Laboratories, Burlingame, CA), and 
the reaction was visualized using diaminobenzidine. The number of BDNF-stained positive cells 
in the BLA and hippocampus were counted manually under an Olympus BH2-RFCA microscope 
at 100x magnification in the 10 month old female mice (n=38). The female mice were divided 
into four groups composed of 10 wild-type, 9 wild-type quetiapine-treated, 9 transgenic, 9 
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transgenic quetiapine-treated. For convenience the BLA was measured in 3 of its distinct regions 
of equal dimesions of 361 mm², they can be defined as the bottom left and right, and top center 
regions of the BLA. The overall average of the 3 seperate regions as a whole was compared. For 
the hippocampus we counted the total number of positive cells in the CA1, CA3, and DG areas, 
and compared the overall average of these 3 regions. All micrographs of representative sections 
were photographed using an Axio-Imager A1, camera Axiocam, and the software Axio-Vision 
version 4 for image acquisition (all from Carl Zeiss, Jena, Germany).  
2.3.2 Staining and Quantification of Amyloid Deposits 
 
Horizontal sections were stained for amyloid deposits with Congo Red solution (Congo 
Red kit, Sigma–Aldrich, St. Louis, MI) after counterstaining with Mayer’s hematoxylin solution 
according to the manufacturer’s protocol. The number of Congo Red-stained amyloid plaques in 
the cortex and the hippocampus were counted under an Olympus BH2-RFCA microscope at 
100x magnification in the 9 month-old mice (He et al., 2007). The total number [<25 μm (small), 
25 to 50μm (medium), and >50μm (large) in diameter] of amyloid plaques in the cortex and the 
hippocampus (three horizontal sections at levels of 2.16, 2.34, and 2.52mm ventral to bregma) 
were counted manually. The size of the total counted area was collected using a Olympus BH2-
RFCA microscope fitted with a Spot-RT digital camera (Diagnostic Instruments, Sterling 
Heights, MI), and analyzed using Image-Pro Plus software (Media Cybernetics, Silver Spring, 
MD). Plaques for which the intensity was not sufficiently above the background to meet the 
proper threshold were not considered. Plaque counting was performed by an investigator who 
was blind to group membership. The plaque number is reported as the total number of plaques 
counted per 10mm² area of the cortex or hippocampus. For the Congo Red staining we used the 9 
month old female (n=48) and male (n=73) mice. Please refer to table 1 for the specific numbers 
of mice in each group at 9 months of age. 
Plaque detection in the 12 month-old mice was also investigated. Micrographs of 
representative sections for the plaque detection of the 12 months old mice were photographed 
using an Axio-Imager A1, camera Axiocam, and the software Axio-Vision version 4 for image 
acquisition (all from Carl Zeiss, Jena, Germany).  
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2.4 Statistical Analysis 
 
The first hypothesis, which addressed the effects of quetiapine on memory in the Y-maze 
and water maze, and anxiety-like behaviours in the ETM, was analyzed using one-way analysis 
of variance (ANOVA) to determine the statistical difference between levels of anxiety among the 
non-transgenic and the APP/PS1 mice.  To test the first hypothesis, an α level was set at 0.05. 
For the behavioural measures, one way ANOVAs were conducted to compare genotype (non-
transgenic and transgenic) within each level of treatment factor (quetiapine: 0, 2.5 and 5 
mg/kg/day) for females. Results of the preliminary analysis showed a high variability in 
treatment effect among the male mice, implying that sex was not a necessary factor to study as 
an interaction or covariate. Therefore the female mice were used in this study. 
To analyze the second hypothesis, which addressed the effects of quetiapine on BDNF 
levels in the amygdala and hippocampus, and on the plaque load in the hippocampus and cortex, 
the significant differences were determined by two-way ANOVA.  This analysis was used to 
observe whether there would be an interaction between genotype (non-transgenic and transgenic) 
and drug (quetiapine: 0, 2.5 and 5 mg/kg/day).  A p value of less than 0.05 was regarded as 
statistically significant.  Newman-Keuls posthoc test for multiple comparisons were conducted. 
A two-tailed t-test for independent samples was used for two-group comparisons. All results 
were expressed as means ± S.E.M.  
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CHAPTER 3: RESULTS 
 
3.1. Conditioned Anxiety and Unconditioned Anxiety in the ETM 
3.1.1. Avoidance 
 
A two-way analysis of variance (ANOVA) showed that there was an interaction of 
treatment group by genotype that approached significance, F(1,54) = 3.923, p = 0.053, for 
female mice. Simple effects tests (Figure 5) comparing transgenic and control groups within 
water treatment revealed that transgenic mice had significantly lower latencies, t(23) = 3.839, p = 
0.0012, compared to controls when receiving water. The t-test, t(22) = -3.602,  p = 0.0017, 
revealed that transgenic mice treated with quetiapine had significantly higher latency in the 
avoidance task than transgenic mice treated with water. Transgenic female mice treated with 
quetiapine were similar to controls and controls treated with quetiapine (Figure 5). There was no 
significant interaction or significant main effect in avoidance latency 1. As previously mentioned 
male mice displayed high variability within the groups and failed to show the effect of treatment.   
3.1.2. Escape 
 
A 2 (genotype) by 2 (treatment) ANOVA of female mice revealed a nonsignificant 
interaction, F(1, 54) = 0.19448, p = 0.661 between genotype and treatment group in the escape 3 
(Figure 8). A main effect of genotype was found and transgenic mice had significantly lower 
escape latencies than control non-transgenic mice,  F(1,54) = 20.09, p < 0.001 (Figure 6). There 
was no main effect of drug treatment, F(1, 54) = 0.919, p = 0.3418.  In the escape latency 1 and 
2 trials, the interaction and main effects were non-significant. 
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3.2. BDNF Levels in the Basolateral Amgydala and the Hippocampus 
3.2.1. Basolateral Amygdala 
 
Figure 7 shows the procedure for counting cells. A non-significant interaction of 
genotype (transgenic versus non-transgenic) by treatment (quetiapine, water) was found, F(1,36) 
= 1.3902, p = 0.2468 (Figure 8). A significant main effect of genotype was found, F(1,33) = 
24.6851, p = 0.0001. The transgenic mice had significantly lower BDNF (M = 102.5432) in the 
BLA compared to control non-transgenic (M = 121.5225). A significant main effect of treatment, 
F(1,36) = 9.9124, p = 0.0035, revealed that quetiapine-treated transgenic mice had significantly 
higher BDNF expression in the BLA compared with the water-treated transgenic mice. Figures 7 
and 9 illustrate representative photomicrographs of BDNF immunostaining in the BLA of 12-
month old female mice.  
3.2.2. Hippocampus 
 
A non-significant interaction of genotype (transgene versus non-transgene) by treatment 
(quetiapine versus water) was found, F(1,36) = 1.4962, p = 0.2299 (Figure 12). A 2 (genotype) 
by 2 (treatment) ANOVA revealed a significant main effect of genotype F(1,33) = 4.1029, p = 
0.051, whereby transgenic mice (M = 1069.6358) had significantly lower BDNF compared to 
control non-transgenic (M = 1158.6488) in females. A significant main effect of treatment, 
F(1,33) = 11.6798, p = 0.0017, revealed that quetiapine treated transgenic female mice (M = 
1189.2346) had significantly higher BDNF in the hippocampus (CA1, 2, 3 and DG) compared to 
water (M = 1039.05) treated female transgenic mice. Figure 10 and 12 illustrate representative 
photomicrographs of BDNF immunostaining in the hippocampus of 12-month old female mice.  
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Figure 6. Avoidance in the elevated T-maze in female mice.  
The effect of genotype (transgene versus control) and treatment group (quetiapine versus water) 
on inhibitory avoidances measured in 3 trials, Baseline, Avoidance 1, and Avoidance 2 in the 
elevated T-maze: Con: Control (non-transgenic); Q5: quetiapine 5 mg/Kg/day in non-transgenic; 
Tg: APP/PS1 double transgenic in water treatment group; Tg+Q5: APP/PS1 double transgenic in 
quetiapine treated group. Quetiapine was administered in drinking water from the age of 2 
months for 10 months. Results are expressed as means±S.E.M. n = 10–18 in each group. *p < 
0.05 vs. Con; #p < 0.05 vs. Tg. 
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Figure 7. Escape in the elevated T-maze in female mice.  
The effect of genotype (transgene versus control) and treatment group (quetiapine versus water) 
on one-way escape measured in 3 trials, Escape 1, Escape 2, and Escape 3 in the elevated T-
maze: Con: Control (non-transgenic); Q5: quetiapine 5 mg/Kg/day in non-transgenic; Tg: 
APP/PS1 double transgenic in water treatment group; Tg+Q5: APP/PS1 double transgenic in 
quetiapine treated group. Quetiapine was administered in drinking water from the age of 2 
months for 10 months. Results are expressed as means±S.E.M. n = 10–18 in each group. *p < 
0.05 vs. Con. 
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Figure 8. Representative photomicrograph of BDNF immunostaining in the amygdala of a 
12 month old female mice treated with quetiapine for 10 months.  
The BDNF positive cells were counted in the highlighted BLA (Basolateral Amygdala) located 
just beside the LA (Lateral Amygdala). Scale bar = 200 μm. 
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Figure 9. Quantitative analysis of BDNF-positive cells in the BLA (Basolateral Amygdala) 
of 12-month old female mice.  
Effects of genotype (transgene versus control) and treatment group (quetiapine versus water) on 
the BDNF-positive cells in the BLA (Basolateral Amygdala) of 12-month old female mice: Con: 
Control (non-transgenic); Q5: quetiapine 5 mg/Kg/day in non-transgenic; Tg: APP/PS1 double 
transgenic in water treatment group; Tg+Q5: APP/PS1 double transgenic in quetiapine 
(5mg/kg/day) treated group. Quetiapine was administered in drinking water from the age of 2 
months. Results are expressed as means±S.E.M. n = 9–10 in each group. *p < 0.05 vs. Con; #p < 
0.05 vs. Tg. 
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Figure 10. Representative photomicrographs of BDNF immunostaining in the BLA 
(Basolateral amygdala) in 12-month old female mice.  
Control (non-transgenic) (A); Q5: quetiapine 5 mg/Kg/day in non-transgenic (B); Tg: APP/PS1 
double transgenic in water treatment group (C); Tg+Q5: APP/PS1 double transgenic in 
quetiapine (5mg/kg/day) treated group (D). Quetiapine was administered in drinking water from 
the age of 2 months; Scale bar = 20 μm. 
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Figure 11. Representative photomicrograph of BDNF immunostaining in the hippocampus 
of a 12-month old female mice treated with quetiapine for 10 months.  
The BDNF positive cells were counted in the CA1 (Cornu Ammonis 1), CA3 (Cornu Ammonis 
3) and DG (Dentate Gyrus) regions of the hippocampus. Scale bar = 200 μm. 
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Figure 12. Quantitative analysis of BDNF-positive cells in the Hippocampus (CA1, CA2, 
CA3, DG) of 12-month old female mice. 
Effects of genotype (transgene versus control) and treatment group (quetiapine versus water) on 
the BDNF-positive cells in the Hippocampus (CA1, CA2, CA3, DG) of 12-month old female 
mice: Con: Control (non-transgenic); Q5: quetiapine 5 mg/Kg/day in non-transgenic; Tg: 
APP/PS1 double transgenic in water treatment group; Tg+Q5: APP/PS1 double transgenic in 
quetiapine (5mg/kg/day) treated group. Quetiapine was administered in drinking water from the 
age of 2 months. Results are expressed as means±S.E.M. n = 9–10 in each group. *p < 0.05 vs. 
Con; #p < 0.05 vs. Tg. 
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Figure 13. Representative photomicrographs of BDNF immunostaining in CA1 pyramidal 
cell layers of the hippocampus in 12-month old female mice.  
Control (non-transgenic) (A); Q5: quetiapine 5 mg/Kg/day in non-transgenic (B); Tg: APP/PS1 
double transgenic in water treatment group (C); Tg+Q5: APP/PS1 double transgenic in 
quetiapine (5mg/kg/day) treated group (D). Quetiapine was administered in drinking water from 
the age of 2 months; Scale bar = 20 μm. 
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3.3. β-Amyloid Plaque Formation in APP/PS1 Mice Treated With Quetiapine 
 
Aβ deposits were not found in the 9-month-old non-transgenic mice.  The number of 
Congo Red-positive plaques in the transgenic mice by treatment group are shown in Figure 13A 
(cortex) and 13B (hippocampus). One-way ANOVAs showed a significantly greater number of 
large plaques in the cortex of transgenic female and male mice, F(2, 59) = 5.71, p = 0.0054 and 
hippocampus, F(2, 59) = 4.71, p = 0.013, medium plaques in the cortex, F(2, 59) = 10.68, p = 
0.0001 and hippocampus, F(2, 59) = 7.54, p = 0.0012, small plaques in the cortex, F(2, 59) = 
12.43, p < 0.0001 and hippocampus, F(2, 59) = 9.62, p = 0.0002, and total plaques in the cortex, 
F(2,59) = 15.47, p < 0.0001, and hippocampus, F(2, 59) = 10.69, p = 0.0001, of 9-month-old 
transgenic mice. Figure 13 illustrates representative photomicrographs of Congo Red staining 
showing Aβ plaques in the cortex of 9-month old APP-PS1 transgenic mice. Plaque deposition 
was also found in the hippocampus (Figure 15B) and BLA (Figure 15D) of 12-month transgenic 
mice. There were no detectable plaques in the 12-month non-transgenic mice (Figure 15A, C). 
 
3.4. Y-Maze Spatial Working Memory in APP/PS1 Mice Compared With Control 
 
In the Y-maze, in which there were 2 levels of drug (0, 2.5, 5 mg/kg/day), 9-month 
females and males were used. The interaction between drug treatment and genotype approached 
significance, F(1, 117) = 29741, p = 0.055 (Figure 16A). A test of simple effects was conducted, 
with an alpha set at 0.01. Newman-Keuls post hoc test revealed lower alternation percentage in 
transgenic mice, F(1,112) = 24.1567 p < 0.01,  compared with the control (non-transgenic treated 
with water). However, higher alternation was found in the transgenic mice treated with 
quetiapine 2.5 mg/kg/day, F(1, 112) = 12.53054, p < 0.01, compared with water treated 
transgenic mice. Higher alternation was also found in the transgenic mice treated with the higher 
dose of quetiapine (5 mg/kg/day), compared with transgenic mice treated with water, F(1, 112) = 
25.34359 p < 0.01 No significant difference was observed for the transgenic mice treated with 
quetiapine 2.5 mg/kg/day, compared with the APP/PS1 treated with 5 mg/kg/day, F(1, 112) = 
.68738, p > 0.05. Overall, transgenic mice treated with water resulted in a lower percentage of 
alternation in comparison with those APP/PS1 treated with quetiapine 2.5 and 5 mg/kg/day. 
APP/PS1 receiving quetiapine 5 mg/kg/day and 2.5 mg/kg/day was no different than controls (p 
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> 0.05). For the 9-month-old mice (Figure 16A), two-way ANOVA showed that genotype 9-
months, F(1, 112) = 24.09, p < 0.0001, and quetiapine 9-month, F(2, 112) = 10.60, p < 0.0001, 
had a significant effect on the alternation performance. There was no difference in the number of 
total arm entries among the groups of 9-month-old mice (Figure 16B). 
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Figure 14. Representative photomicrographs of Congo Red staining showing Aβ plaques in 
the cortex and hippocampus of 9-month of age APP/PS1 mice. 
Aβ plaques in the cortex of 9-month transgenic (A), transgenic + quetiapine 2.5 mg/kg/day (B), 
and transgenic + quetiapine 5 mg/kg/day (C) mice; in the hippocampus of 9-month transgenic 
(D), transgenic + quetiapine 2.5 mg/kg/day (E), and transgenic + quetiapine 5 mg/kg/day (F) 
mice. The arrows indicate the positive Aß plaques of Congo Red staining. Scale bar = 90 μm. 
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Figure 15. Quantitative analysis of plaques by Congo Red staining in the cortex and 
hippocampus.  
Quantitative analysis of Congo Red staining showing chronic administration of quetiapine on the 
number of large (>50 μm in diameter), medium (25–50 μm in diameter), small (<25 μm in 
diameter), and total (large + medium + small) plaques (per mm²), in the cortex (A) and 
hippocampus (B) of 9-month old male and female transgenic mice. Tg: APP/PS1 transgenic in 
water treatment group; Tg+Q2.5: APP/PS1 transgenic in quetiapine 2.5mg/kg/day treated group; 
Tg+Q5: APP/PS1 transgenic in quetiapine 5mg/kg/day treated group. Quetiapine was 
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administered in drinking water from the age of 2 months. Results are expressed as means±S.E.M. 
n = 4–16 in each group. Con; #p < 0.05 vs. Tg.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Representative photomicrographs of Congo Red staining showing Aβ plaques in 
the hippocampus and BLA of 12-month of age APP/PS1 mice. 
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Aβ plaques in the hippocampus of 12-month non-transgenic (A), APP/PS1 transgenic (B) mice, 
and in the BLA of 12-month non-transgenic (C), APP/PS1 transgenic (D) mice. The arrows 
indicate the positive Aß plaques of Congo Red staining. Scale bar = 200 μm. 
 
 
 
Figure 17. Y-maze test in 9-month old mice.  
Effects of genotype (transgene versus control) and treatment group (quetiapine versus water) on 
the alternation performance (A), and on the number of total arm entries (B) in a Y-maze test in 9 
month old non-transgenic and transgenic male and female mice: Con: Control (non-transgenic); 
Q5: quetiapine 5 mg/Kg/day in non-transgenic Q2.5: quetiapine 2.5 mg/Kg/day in non-
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transgenic; Tg: APP/PS1 double transgenic in water treatment group; Tg+Q2.5: APP/PS1 double 
transgenic in quetiapine 2.5mg/kg/day treated group; Tg+Q5: APP/PS1 double transgenic in 
quetiapine 5mg/kg/day treated group. Quetiapine was administered in drinking water from the 
age of 2 months. Results are expressed as means±S.E.M. *p < 0.05 vs. Con; #p < 0.05 vs. Tg. 
 
3.5. Learning and Memory in the Water Maze  
 
There were significant 2-way interactions between genotype and treatment group in the 
9-month old mice, F(2, 112) = 3.82, p = 0.025, and between genotype and training, F(3, 336) = 
3.67, p = 0.013. For the 9-month-old mice, there was a 3-way interaction among genotype, 
treatment, and training, F(6, 336) = 2.63, p = 0.017. A Newman Keuls post hoc analysis 
indicated that the escape latency in blocks 2, 3, and 4 for the transgenic mice was higher than for 
the non-transgenic control mice, and that quetiapine significantly prevented the increase of 
escape latency in the transgenic mice (Figure 16A). In the probe test of the control mice, the 
mice spent more time (%) in the target quadrant than in the other quadrants, (p < 0.05). In the 
probe test of the (Figure 16B), two-way ANOVA showed that genotype, F(1, 112) = 24.21, p < 
0.0001 and treatment, F(2, 112) = 3.30, p = 0.040, had effects on the time (%) spent searching 
for the target quadrant, and that there was interaction between genotype and treatment, F(2, 112) 
= 4.45, p = 0.014. A Newman Keuls post hoc analysis indicated that the transgenic mice spent 
less time (%) in the target quadrant compared to the control animals, and that quetiapine 
significantly prevented the decrease in time (%) in the target quadrant in the transgenic mice 
(Figure 16B). There was no statistical difference in the swimming speed among the groups of 9-
month-old mice in the learning or the probe trials. 
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Figure 18. Escape latency of the hidden-platform test and percentage of time in the probe 
test. 
Effects of chronic administration of quetiapine on the escape latency of the hidden-platform test 
(A), and on the percentage of time in the target quadrant (trained) of the probe test (B) in the 
water maze test in 9 month old non-transgenic and transgenic mice. Control (non-transgenic); 
Q5: quetiapine 5 mg/Kg/day in non-transgenic Q2.5: quetiapine 2.5 mg/Kg/day in non-
transgenic; Tg: APP/PS1 double transgenic in water treatment group; Tg+Q2.5: APP/PS1 double 
transgenic in quetiapine 2.5mg/kg/day treated group; Tg+Q5: APP/PS1 double transgenic in 
quetiapine 5mg/kg/day treated group. Quetiapine was administered in drinking water from the 
age of 2 months. Results are expressed as means±S.E.M. *p < 0.05 vs. Con; #p < 0.05 vs. Tg. 
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CHAPTER 4: DISCUSSION 
 
The purpose of this study was to examine the effects of quetiapine on anxiety-like 
behaviour in an APP/PS1 double transgenic mouse model of AD and to investigate the 
relationship between anxiety and BDNF levels in the BLA and hippocampus in these same mice. 
This study also helped to clarify the conflicting findings reported in recent studies that 
investigated anxiety in the APP/PS1 and the long-term effects of quetiapine on anxiety in AD 
models. This study was designed to investigate the relation of anxiety and memory impairment 
in a mouse model of AD, and to evaluate a potential drug treatment for anxiety in the same 
model.  Spatial memory was examined using the Y-maze and Water maze test. Anxiety was 
examined using the ETM task. This study contributes to not only understanding the relationship 
between BPSD and memory deficits, it also has implications for early diagnoses and drug 
intervention in AD patients. Finally, the present study contributes to the literature pertaining to 
the neuroprotective effects of quetiapine on Aβ plaques, memory impairments, anxiety-like 
behaviours and BDNF levels. 
This discussion is comprised of five main sections. The first section discusses that, 
similar to previous reports (see He et al., 2007), the present study confirms the presence of an 
accumulation of Aβ plaque load and memory impairment in the APP/PSI double transgenic 
mice. The second section discusses the expression of conditioned anxiety in the ETM task, and 
incorporates statistical analyses for the transgene and wild-type groups not receiving quetiapine 
treatment as a measure of reliability of the ETM in eliciting conditioned anxiety in the groups. 
The third section discusses the effect of chronic administration of quetiapine treatment on 
conditioned anxiety in the APP/PS1. In the fourth section, a discussion of the role of BDNF in 
the BLA and hippocampus of the transgene mice is presented, integrating statistical analyses of 
the groups. The fifth section presents a discussion pertaining to implications of the theoretical 
model in this study as well as future research. 
Alzheimer’s disease, a neurodegenerative disorder affecting ~2% of the population in 
industrialized countries (http://www.alz.org), is characterized by cognitive and memory 
deterioration, progressive impairment of activities of daily living, and a variety of 
neuropsychiatric symptoms. Atypical antipsychotics are widely used to treat psychotic 
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symptoms, aggression, and agitation associated with AD (Caballero et al., 2006; Street et al., 
2000; Wolfgang, 1999). There is increasing evidence that quetiapine has neuroprotective effects 
in neurodegenerative diseases (Wang et al., 2005), however, it is not known if it can reverse the 
pathological changes that occur in AD and reduce the cognitive and behavioural phenotypes that 
follow. This project is important because it addresses the mechanisms underlying quetiapine’s 
preventive and therapeutic effects in AD. It also enhances our understanding of the 
pathophysiology of AD and will facilitate the development of novel therapeutic strategies in the 
treatment of 
4.1 Report of Aβ plaque load and memory impairment 
AD. Transgenic mice overexpressing genes whose mutations are associated with 
familial AD, such as APP (Hsiao et al., 1996), PS1 (Duff et al., 1996) or PS2 (Oyama et al., 
1998), have been shown to mimic many of the distinguishing traits of AD, including memory 
impairment, amyloid plaques, tauopathy, neuronal loss and gliosis. APP transgenic mice show 
marked elevation of Aβ peptide level and plaques in the cerebral cortex and hippocampus from 
approximately 9-12 month old mice (Hsiao et al., 1996). Mutant PS1 transgenic mice do not 
show abnormal pathology, but do display subtly elevated levels of the Aβ42/43 peptide (Duff et 
al., 1996). Transgenic mouse models of AD that carry APP and/or PS1 mutated genes do develop 
AD-like pathology and memory impairment, and are useful for testing possible drug therapeutics 
of AD (Holcomb et al., 1998; Hsiao et al.; Games et al., 1995; Sturchler-Pierrat et al., 1997). 
Double transgenic mice carrying both APP and PS1 mutations show accelerated Alzheimer 
phenotype compared with APP single transgenic mice (Holcomb et al.). The APP/PS1 double 
transgenic mice are, therefore, useful in the study of AD. 
 
 
Consistent with previous reports (Arendash et al., 2001; Holcomb et al., 1998; Matsuoka 
et al., 2001), APP/PS1 transgenic mice in the present study demonstrated memory impairment 
and high levels of Aβ plaques. Chronic administration of quetiapine prevented the alternation 
behaviour impairment, acquisition and retention impairment in the transgenics, suggesting the 
overall improvement of spatial memory. However, one of the limitations regards the sample size 
of our subjects. Although there were significant differences between the groups, the number of 
mice used to assess memory impairment was small and a future study investigating the effects of 
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atypical antipsychotics including quetiapine should account for this limitation. Chronic 
administration of quetiapine also decreased the number Aβ plaques in the APP/PS1.  
According to Holcomb et al. (1998), memory impairment and increased Aβ plaques may 
occur almost at the same time point or, as the present study revealed, memory impairment may 
occur following Aβ plaques (He et al., 2007). In support of the present study’s findings, previous 
studies have concluded that memory impairment may be associated with increased brain Aβ 
plaque deposits (Arendash et al., 2001; Puoliväli et al., 2002). Furthermore, increased brain Aβ 
plaques may be the primary influence resulting in neuronal degeneration in AD (Hardy and 
Selkoe, 2002), impaired long term potentiation in APP/PS1 transgenic mice (Chapman et al., 
1999), and the inflammatory responses demonstrated in a transgenic model of AD (Matsuoka et 
al., 2001). Therefore, the beneficial effects of the chronic administration of quetiapine on 
memory impairment in the transgenic mice may in turn be associated with decreasing the 
formation of brain Aβ plaques. 
 
4.2. Phenotype of Conditioned Anxiety and Unconditioned Anxiety in the ETM 
 
In parallel with other studies on anxiety-like behaviours in the APP/PS1 mouse (He et al. 
2007; Jensen et al. 2005; Ognibene et al. 2005; Pugh et al. 2007), the findings in the present 
study confirm impaired anxiety-like behaviour. Conditioned anxiety can be related to GAD and 
unconditioned anxiety can be related to PD. In reference to our first hypothesis, avoidance (third 
trial) of the ETM revealed impaired conditioned anxiety in the female transgenic mice. However, 
one of the limitations is that the male mice displayed high variability within the groups and 
higher latencies then females (not shown), this can be considered as an indication of an overall 
increased level of anxiety in the male mice. One obvious explenation is that all males were 
individually housed –because of aggressive behaviour in the transgenic males– compared to 
females that were caged in groups of 4 to 5. Social isolation has already been described in the 
past to increase levels of anxiety (Hilakivi, Ota, & Lister, 1989). Unfortunetly, there is no way to 
avoid this; we must maintain the safety and comfort of the animals. Also the escape (third trial) 
of the ETM revealed impaired unconditioned anxiety in the female transgenic mice. More 
specifically, the avoidance and escape latencies were decreased in transgenic female mice, at 12 
months of age in comparison with the control group.  Chronic administration of quetiapine 
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resulted in an increase of the avoidance latency in the transgenic females to control levels during 
the avoidance 2 phase, but did not alter the escape latency.  
 
4.3. Chronic Administration of Quetiapine: Effect on Conditioned Anxiety 
 
In order to test the therapeutic effects of quetiapine in treating the behaviours, the 
APP/PS1 transgenic mouse model of AD was used in this study. The mice were treated with 
quetiapine beginning at the age of 2 months. Chronic administration of quetiapine improved the 
impaired anxiety-like behaviour. In the present study, quetiapine seemed to normalize the 
conditioned anxiety-like behaviour in the ETM in female transgenic mice. In other words, 
quetiapine increased the latency of the APP/PS1 in the avoidance 2, suggesting that the mice 
remembered the anxiogenic environment. To date, this conclusion has not been documented 
elsewhere. The APP/PS1 showed panic-like symptoms in the escape 3 phase. However, no 
significant difference was observed with the treatment for the escape latency implying that the 
treatment did not have an effect on the panic-like behaviour or unconditioned anxiety. The 
avoidance is a reliable expression of conditioned anxiety in these transgenic mice, and the ETM 
is a useful tool for the study of conditioned anxiety in mice. Consistent with present findings, 
Carvalho-Netto and Nunes-de-Souza (2004) suggested there is no effect from any treatment on 
mice that exhibit unconditioned anxiety or escape behaviour. Consequently, it is challenging to 
use the latency to leave the open arms as a useful parameter in this model for mice.  
Quetiapine maintained the BDNF levels in the transgenic females. This drug significantly 
increased the BDNF positive cells to normal levels in the amygdala and hippocampal area of 
female APP/PS1. Quetiapine may have indirectly caused the observed behaviours by its potential 
neuroprotective effects. Such findings highlight that the effects of quetiapine on anxiety-like 
changes may be affecting the progression of memory and pathological changes. 
 
4.4. Role of BDNF in BLA and Hippocampus 
 
Reduced expression of BDNF mRNA levels has been observed in human post-mortem 
AD patients’ hippocampi and temporal corteces (Connor et al., 1997). The loss of BDNF may 
contribute to the progressive atrophy of neurons in AD. Further, the Aβ plaque deposition and 
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neurofibrillary tangles are found mainly in the brain regions involved with cognition and 
emotional behaviour, such as the entorhinal cortex, hippocampus, basal forebrain and amygdala 
(Mattson, 2004).  Connor et al. and Mattson (2004) reported that other regions could contribute 
to the pathology associated with the behaviours found in AD; however this study focused on the 
amygdala and hippocampus.   Ou and Gean (2007) suggested that BDNF in the amygdala is a 
marker for the acquisition of conditioned anxiety. Our data suggest that quetiapine is beneficial 
in treating anxiety by normalizing the anxiety levels related to memory impairment, and 
increasing neuroprotectant factors in AD patients. Prior to the present study, quetiapine’s ability 
to normalize conditioned-anxiety in the mouse model of AD had not been reported. More 
recently, He et al. (2007) found that quetiapine was effective in treating anxiety-like behaviours 
and pathological changes in the APP/PS1 mouse model of AD; further supporting its 
neuroprotective function in treating neurodegenerative diseases. On the other hand, one reason 
for the uncertain effects of quetiapine on cognition may be that the neuroprotective effects might 
be weakened or even lost as the AD-pathology progresses.  
Alzheimer’s Disease is caused by a series of biological risks and stressors (Cummings & 
Zhong, 2006). Biological risks include genetic factors and age; stressors include environmental 
factors and diet. Together these factors will promote the over-expression and abnormal 
processing of APP, misfolding of this protein or the inability to clear the expressed Aβ, all of 
which could contribute to aggregation and amyloid plaque formation. In addition, the 
hyperphosphorilation of tau, a microtubule-associated protein, will result in the self-assembly of 
neurofibrillary tangles made up of paired helical filaments and straight filaments inside neurons. 
Then microtubules disintegrate, causing the neuron’s transport system to collapse and result in 
malfunctions in biochemical communication. Together, the amyloid plaques and the tau protein 
abnormalities produce inflammation, oxidation, excitotoxicity, apoptosis, and receptor and 
neurotransmitter deficits. Pathological changes in the limbic regions induce the psychological 
and behavioural symptoms of dementia and changes in neocortical regions produce the cognitive 
impairments (Cummings & Zhong).  
Currently, studies have demonstrated the effectiveness of atypical antipsychotics for 
treating cognitive impairment, neurodegeneration (Carson, McDonagh & Peterson, 2006), and 
more recently BPSD (Rocca et al., 2008). Atypical antipsychotics, including quetiapine, are used 
in treating patients with BPSD such as psychoses, aggression and agitation (Caballero et al., 
 69 
 
2006; Scharre & Chang, 2002; Street et al., 2000). It has already been suggested that quetiapine 
can alleviate cognitive impairment and pathological changes in the APP/PS1, and further 
indicate that quetiapine may be beneficial in treating AD (He et al., 2007).  
In this study we demonstrated the effects of quetiapine on anxiety-like behaviour in the 
APP/PS1 mouse. As previously mentioned, BDNF is a neurotrophic factor involved in growth, 
survival and differentiation of new neurons. There is a strong relationship between BDNF levels 
and mood disorders (Duman 2004; Hashimoto, Shimizu, & Iyo, 2004). Evidence suggests that 
BDNF has trophic effects on serotonergic (Mamounas et al., 2000), noradrenergic (Fawcett et al., 
1998), dopaminergic (Lara, Kusano, House, & Gainer, 2003), and cholinergic neurons (Koliatsos 
et al., 1994). Quetiapine’s beneficial effects on anxiety-like behaviours may be associated with 
the blockade of BDNF decrease (Figure 11). Quetiapine may be beneficial as a neuroprotectant 
in treating the BPSD associated with AD. Similarily, chronic administration (21 days) of 
quetiapine (10 mg/kg) alleviated the BDNF mRNA decrease in the hippocampus of rats caused 
by immobilization stress (Xu et al., 2002). A single dose of quetiapine also increased BDNF 
mRNA expression in the rat hippocampus when treated with the NMDA antagonist MK-801, but 
not in the cortex (Fumagalli et al., 2004). More recently, Park et al. (2006) demonstrated that 
chronic administration of quetiapine significantly alleviated the decreased BDNF mRNA 
expression in the both hippocampus and cortex caused by stress-induced immobilization, and 
significantly increased the BDNF mRNA expression in the dentate gyrus of rats without stress-
induced immobilization.  
 
4. 5. General Discussion and Implications of Future Research 
 
In order to advance knowledge regarding anxiety in AD, our future aim will be to examine 
age and sex differences in the APP/PS1. It is possible that age is a potential covariate in the 
expression of conditioned anxiety. For instance, in one study (Küçük, Gölgeli, Saraymen, & 
Koç, 2008), the avoidance latency increased with age in the ETM, which the authors suggested 
might be linked to memory impairment. Further studies are needed to investigate different age 
groups and sex to determine whether they display the conditioned anxiety that we observed in 12 
month old mice.  
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Ou and Gean (2007) highlighted the signal cascades linking the initial physiological events 
by which anxiety conditioning modulates the expression of BDNF in the lateral amygdala. It is 
critical that future studies focus on the mechanism through which quetiapine exerts its beneficial 
effect on conditioned anxiety in the APP/PS1 mice. In summary, studies are necessary to 
elucidate the direct and/or indirect factors that may be involved in quetiapine’s regulation of 
BDNF in these transgenic mice. Future studies should also include investigations on the precise 
processes involved in other atypical antipsychotics and on other neurotrophic factors.  
 As with the study done by He et al. (2007), the current findings suggest that quetiapine 
may be useful in treating the BPSD, memory impairment and pathological changes associated 
with AD. However, what is unique to our study is that chronic administration of quetiapine 
tended to normalize the ETM-induced conditioned anxiety-like behaviour and prevented the 
BDNF decrease in the BLA of female APP/PS1. Furthermore, consistent with the clinical study 
of Savaskan et al. (2006), the current study highlights the possible effects of quetiapine on 
specific anxiety-like (GAD) behaviours and the link with BDNF changes in the amygdala of 
APP/PS1 mouse model of AD.  This is the first study to demonstrate this in an animal model of 
AD. Future studies should assess the effect of other atypical antipsychotic drugs on inhibitory 
avoidance in the APP/PS1. 
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Figure 19. Conceptual model of Alzheimer’s disease and quetiapine’s therapeutic effects 
through BDNF. 
The risk of developing Alzheimer’s disease may be increased by biological factors such as 
genetic predispositions, ageing; and environmental stressors such as diet. These may induce 
pathological changes in overexpression, misfolding and aggregation of Aβ in the brain. 
Depending on the damaged area, it may provoke behavioural changes such as anxiety in the 
limbic regions or cognitive impairment such as memory loss in neocortical regions. Quetiapine 
may be useful in treating the behavioural and psychological symptoms of dementia (BPSD), 
memory impairment and pathological changes. One of quetiapine’s pathways may be by 
increasing BDNF levels in the hippocampus and the amygdala. 
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